PSIVIDA LIMITED | ||
|
|
|
By: | /s/Aaron Finlay | |
Aaron Finlay |
||
Company Secretary |
EXHIBIT
99.1:
|
pSivida
2006 Financial Statements reconciled to
US-GAAP
|
Years
ended June 30,
|
|||||||
2006
|
2005
|
||||||
(In
Australian Dollars)
|
|||||||
STATEMENT
OF OPERATIONS DATA:
|
|||||||
A-IFRS
|
|||||||
Revenue
|
1,393,000
|
161,666
|
|||||
Loss
before income tax
|
(37,685,934
|
)
|
(20,813,923
|
)
|
|||
Net
loss
|
(28,166,129
|
)
|
(16,793,836
|
)
|
|||
Loss
per share - basic and diluted
|
(0.09
|
)
|
(0.08
|
)
|
As
of June 30,
|
|||||||
2006
|
2005
|
||||||
(In
Australian Dollars)
|
|||||||
BALANCE
SHEET DATA:
|
|||||||
A-IFRS | |||||||
Total
assets
|
235,486,077
|
91,866,102
|
|||||
Net
assets
|
175,032,585
|
79,695,747
|
|||||
Contributed
equity
|
230,377,035
|
107,883,835
|
Years
ended June 30,
|
||||||||||||||||
2006
|
2005
|
2004
|
2003
|
2002
|
||||||||||||
(In
Australian Dollars)
|
||||||||||||||||
STATEMENT
OF OPERATIONS DATA:
|
||||||||||||||||
U.S.
GAAP
|
||||||||||||||||
Revenue
|
1,393,000
|
161,666
|
56,200
|
-
|
N/A
|
|||||||||||
Loss
from operations
|
(72,221,844
|
)
|
(20,560,679
|
)
|
(10,195,615
|
)
|
(6,076,013
|
)
|
N/A
|
|||||||
Net
loss
|
(63,481,126
|
)
|
(16,561,512
|
)
|
(5,019,974
|
)
|
(2,268,603
|
)
|
N/A
|
|||||||
Loss
per share - basic and diluted
|
(0.21
|
)
|
(0.08
|
)
|
(0.04
|
)
|
(0.02
|
)
|
N/A
|
As
of June 30,
|
||||||||||||||||
2006
|
2005
|
2004
|
2003
|
2002
|
||||||||||||
(In
Australian Dollars)
|
||||||||||||||||
BALANCE
SHEET DATA:
|
||||||||||||||||
U.S.
GAAP
|
||||||||||||||||
Total
assets
|
219,903,245
|
100,063,276
|
41,295,099
|
8,220,492
|
N/A
|
|||||||||||
Net
assets
|
172,598,133
|
87,650,337
|
37,794,706
|
7,140,316
|
N/A
|
|||||||||||
Contributed
equity
|
269,361,617
|
117,798,149
|
51,030,718
|
15,428,635
|
N/A
|
The
DurasertTM
technology, obtained as part of the acquisition of CDS, uses a drug
core
with one or more surrounding polymer layers. The drug permeates through
the polymers into the body at a controlled and pre-determined rate
for
extended periods of time. Two products - Vitrasert™ and Retisert™ - are
FDA approved and licensed to Bausch & Lomb, and a third product
candidate, Medidur™ is in phase III trials with our collaboration partner,
Alimera Sciences.
|
BioSilicon™,
which uses nanostructured elemental silicon, has been shown to be
biodegradable and biocompatible. BrachySil™, a targeted oncology product
which comprises a combination of BioSilicon™ and the isotope 32Phosphorus,
a proven anti-cancer therapeutic, is in phase II clinical trials
for the
treatment of primary liver cancer and pancreatic cancer. BioSilicon
offers
multiple other potential applications across the healthcare sector,
including controlled slow release drug delivery, tissue engineering
and
orthopedics.
|
CoDrug™
allows for the simultaneous release of two or more drugs at a controlled
rate from the same product. A library of CoDrug™ compounds has been
synthesized and Phase I clinical trials have been undertaken for
post-surgical and two dermatological
indications.
|
Month
|
High
|
Low
|
|||||
April
2006
|
0.7109
|
0.7604
|
|||||
May
2006
|
0.7781
|
0.7509
|
|||||
June
2006
|
0.7527
|
0.7284
|
|||||
July
2006
|
0.7664
|
0.7407
|
|||||
August
2006
|
0.7699
|
0.7568
|
|||||
September
2006
|
0.7704
|
0.7461
|
Year
ended June 30,
|
At
period end
|
Average
rate
|
High
|
Low
|
|||||||||
2002
|
|
|
0.5628
|
|
|
0.5237
|
|
|
0.5748
|
|
|
0.4841
|
|
2003
|
|
|
0.6713
|
|
|
0.5844
|
|
|
0.6729
|
|
|
0.5280
|
|
2004
|
|
|
0.6952
|
|
|
0.7134
|
|
|
0.7979
|
|
|
0.6390
|
|
2005
|
|
|
0.7618
|
|
|
0.7534
|
|
|
0.7974
|
|
|
0.6880
|
|
2006
|
|
|
0.7423
|
|
|
0.7475
|
|
|
0.7781
|
|
|
0.7056
|
§
|
in
September 2005, we issued 665,000 ADSs (representing 6,650,000 of our
ordinary shares) at a price of US$6.50 (A$8.48) each, raising
A$5.6 million before costs of A$468,873 through a private investment
in public equity (“PIPE”);
|
§
|
in
November 2005, we issued a subordinated convertible promissory note
in the principal amount of US$15 million (A$20.5 million) before
costs of A$607,196 to an institutional investor. That note was amended
and
partially repaid via a payment of US$3.5 million in August 2006
and is currently in the principal amount of US$12,500,000 and convertible
into 6,250,000 ADSs at a conversion price of US$2.00 per ADS, subject
to
adjustment based on certain events or circumstances, including a
reset
provision based on the market price as of April 30, 2007;
and
|
§
|
in
June 2006, we issued 10,515,811 new ordinary shares at a price of
A$0.60
each, raising A$6,309,487, before costs, through a Rights
Issue
|
§
|
Costs
and timing of obtaining regulatory
approvals;
|
§
|
The
costs and timing of obtaining, enforcing and defending our patent
and
intellectual property;
|
§
|
The
progress and success of pre-clinical and clinical trials of BioSilicon™
and Durasert™;
|
§
|
The
timing and degree of Retisert™ product sales resulting in royalty revenue;
|
§
|
The
progress and number of our research programs in development;
and
|
§
|
The
success, if any, related to the ongoing evaluations of our technology
by
third parties.
|
Notes
|
Years
Ended 30 June,
|
|||||||||
2006
|
2005
|
|||||||||
$
|
$
|
|||||||||
Revenue
|
2(a)
|
|
1,393,000
|
161,666
|
||||||
Other
income
|
580,633
|
660,400
|
||||||||
Selling,
general and administrative
|
(21,392,944
|
)
|
(11,693,006
|
)
|
||||||
Research
and development
|
(17,855,265
|
)
|
(8,287,930
|
)
|
||||||
Finance
costs
|
(4,544,084
|
)
|
(31,569
|
)
|
||||||
Change
in fair value of derivative
|
3,407,915
|
-
|
||||||||
Foreign
exchange gain / (loss), net
|
724,811
|
(1,623,484
|
)
|
|||||||
Loss
before income tax
|
2(b)
|
|
(37,685,934
|
)
|
(20,813,923
|
)
|
||||
Income
tax benefit
|
3(a)
|
|
9,519,805
|
3,620,891
|
||||||
Loss
for the year
|
(28,166,129
|
)
|
(17,193,032
|
)
|
||||||
Loss
attributable to minority interest
|
16
|
-
|
399,196
|
|||||||
Loss
attributable to members of the parent entity
|
15
|
(28,166,129
|
)
|
(16,793,836
|
)
|
|||||
Basic
loss per share
|
22
|
(0.09
|
)
|
(0.08
|
)
|
|||||
Diluted
loss per share
|
22
|
(0.09
|
)
|
(0.08
|
)
|
Notes
|
As
at 30 June,
|
|||||||||
2006
|
2005
|
|||||||||
$
|
$
|
|||||||||
Current
Assets
|
||||||||||
Cash
and cash equivalents
|
17(a)
|
|
15,446,552
|
12,892,061
|
||||||
Trade
and other receivables
|
5
|
1,001,486
|
709,418
|
|||||||
Prepayments
|
632,154
|
322,933
|
||||||||
Total
Current Assets
|
17,080,192
|
13,924,412
|
||||||||
Non-Current
Assets
|
||||||||||
Property,
plant and equipment, net
|
6
|
3,139,549
|
3,273,663
|
|||||||
Goodwill
|
7
|
53,159,229
|
23,305,698
|
|||||||
Other
intangible assets
|
8
|
162,107,107
|
51,362,329
|
|||||||
Total
Non-Current Assets
|
218,405,885
|
77,941,690
|
||||||||
Total
Assets
|
235,486,077
|
91,866,102
|
||||||||
Current
Liabilities
|
||||||||||
Trade
and other payables
|
9
|
7,416,013
|
1,967,718
|
|||||||
Other
payables, related party
|
9
|
-
|
50,102
|
|||||||
Deferred
revenue
|
2,668,574
|
-
|
||||||||
Borrowings
|
10
|
11,219,697
|
-
|
|||||||
Other
financial liabilities
|
11
|
2,465,416
|
-
|
|||||||
Provisions
|
12
|
192,920
|
29,879
|
|||||||
Total
Current Liabilities
|
23,962,620
|
2,047,699
|
||||||||
Non-Current
Liabilities
|
||||||||||
Borrowings
|
10
|
3,940,092
|
-
|
|||||||
Deferred
tax liabilities
|
3(c)
|
|
32,550,780
|
10,122,656
|
||||||
Total
Non-current Liabilities
|
36,490,872
|
10,122,656
|
||||||||
Total
Liabilities
|
60,453,492
|
12,170,355
|
||||||||
Net
Assets
|
175,032,585
|
79,695,747
|
||||||||
Equity
|
||||||||||
Issued
capital
|
13
|
230,377,035
|
107,883,835
|
|||||||
Reserves
|
14
|
1,583,894
|
574,127
|
|||||||
Deficit
accumulated prior to development stage
|
15(a)
|
|
(3,813,181
|
)
|
(3,813,181
|
)
|
||||
Deficit
accumulated during development stage
|
15(b)
|
|
(53,115,163
|
)
|
(24,949,034
|
)
|
||||
Total
Equity
|
175,032,585
|
79,695,747
|
Consolidated
|
||||||||||||||||||||||
Issued
capital
|
Foreign
currency translation reserve
|
Option
premium reserve
|
Employee
equity-settled benefits reserve
|
Accumulated
deficit
|
Minority
interest
|
Total
|
||||||||||||||||
$
|
$
|
$
|
$
|
$
|
$
|
$
|
||||||||||||||||
Balance
at July 1, 2004
|
49,957,982
|
-
|
-
|
39,689
|
(11,968,379
|
)
|
1,583,200
|
39,612,492
|
||||||||||||||
Loss
attributable to members of the parent entity
|
-
|
-
|
-
|
-
|
(16,793,836
|
)
|
-
|
(16,793,836
|
)
|
|||||||||||||
Exchange
differences arising on translation of foreign operations
|
-
|
(350,287
|
)
|
-
|
-
|
-
|
79,361
|
(270,926
|
)
|
|||||||||||||
Minority
interest share of loss
|
-
|
-
|
-
|
-
|
-
|
(399,196
|
)
|
(399,196
|
)
|
|||||||||||||
Total
recognized income and expense for the year
|
-
|
(350,287
|
)
|
-
|
-
|
(16,793,836
|
)
|
(319,835
|
)
|
(17,463,958
|
)
|
|||||||||||
Share-based
payments issued as consideration for acquisition, net of issue
costs
|
57,925,853
|
-
|
292,828
|
-
|
-
|
-
|
58,218,681
|
|||||||||||||||
Share-based
compensation attributable to options issued
|
-
|
-
|
-
|
591,897
|
-
|
-
|
591,897
|
|||||||||||||||
Reversal
of minority interest due to acquisition
|
-
|
-
|
-
|
-
|
-
|
(1,263,365
|
)
|
(1,263,365
|
)
|
|||||||||||||
Balance
at June 30, 2005
|
107,883,835
|
(350,287
|
)
|
292,828
|
631,586
|
(28,762,215
|
)
|
-
|
79,695,747
|
|||||||||||||
Balance
at July 1, 2005
|
107,883,835
|
(350,287
|
)
|
292,828
|
631,586
|
(28,762,215
|
)
|
-
|
79,695,747
|
|||||||||||||
Loss
attributable to members of the parent entity
|
-
|
-
|
-
|
-
|
(28,166,129
|
)
|
-
|
(28,166,129
|
)
|
|||||||||||||
Exchange
differences arising on translation of foreign operations
|
-
|
(2,673,668
|
)
|
-
|
-
|
-
|
-
|
(2,673,668
|
)
|
|||||||||||||
Total
recognized income and expense for the year
|
-
|
(2,673,668
|
)
|
-
|
-
|
(28,166,129
|
)
|
-
|
(30,839,797
|
)
|
||||||||||||
Shares
issued for cash, net of issue costs
|
10,988,877
|
-
|
-
|
-
|
-
|
-
|
10,988,877
|
|||||||||||||||
Share-based
payments issued as consideration for acquisition, net of issue and
registration costs
|
110,805,519
|
-
|
642,251
|
-
|
-
|
-
|
111,447,770
|
|||||||||||||||
Equity
portion of convertible note
|
-
|
-
|
1,706,592
|
-
|
-
|
-
|
1,706,592
|
|||||||||||||||
Exercise
of options
|
27,506
|
-
|
(27,506
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||
Share-based
compensation attributable to nonvested ADSs, options and warrants
issued
|
671,298
|
-
|
72,860
|
1,289,238
|
-
|
-
|
2,033,396
|
|||||||||||||||
Balance
at June 30, 2006
|
230,377,035
|
(3,023,955
|
)
|
2,687,025
|
1,920,824
|
(56,928,344
|
)
|
-
|
175,032,585
|
Notes
|
Years
Ended June 30,
|
|||||||||
2006
|
2005
|
|||||||||
$
|
$
|
|||||||||
Cash
flows from operating activities
|
||||||||||
Receipts
from customers
|
1,982,174
|
-
|
||||||||
Payments
to suppliers, employees and consultants
|
(10,860,228
|
)
|
(4,815,520
|
)
|
||||||
Interest
received
|
574,582
|
667,310
|
||||||||
Income
tax paid
|
-
|
-
|
||||||||
Research
and development expenditure paid
|
(12,980,180
|
)
|
(8,318,054
|
)
|
||||||
Income
received in advance
|
486,780
|
-
|
||||||||
Other
revenue received
|
68,931
|
161,666
|
||||||||
Interest
paid
|
(1,007,752
|
)
|
-
|
|||||||
Net
cash used in operating activities
|
17(b)
|
|
(21,735,693
|
)
|
(12,304,598
|
)
|
||||
Cash
flows from investing activities
|
||||||||||
Purchase
of property, plant and equipment
|
(1,554,681
|
)
|
(3,410,218
|
)
|
||||||
Proceeds
from sale of property, plant and equipment
|
25,906
|
-
|
||||||||
Net
cash paid for acquisition of business
|
17(d)
|
|
(4,033,058
|
)
|
-
|
|||||
Net
cash paid for increased interest in subsidiary
|
-
|
(4,644,964
|
)
|
|||||||
Net
cash used in investing activities
|
(5,561,833
|
)
|
(8,055,182
|
)
|
||||||
Cash
flows from financing activities
|
||||||||||
Proceeds
from issue of ordinary shares
|
11,945,604
|
3,666,500
|
||||||||
Payment
of share issue and registration costs
|
(2,045,430
|
)
|
(27,422
|
)
|
||||||
Proceeds
from borrowings
|
20,500,500
|
-
|
||||||||
Payment
of borrowing costs
|
(1,238,959
|
)
|
-
|
|||||||
Net
cash provided by financing activities
|
29,161,715
|
3,639,078
|
||||||||
Net
increase / (decrease) in cash and cash
equivalents
|
1,864,189
|
(16,720,702
|
)
|
|||||||
Cash
and cash equivalents at the beginning of the financial
year
|
12,892,061
|
31,350,656
|
||||||||
Effects
of exchange rate changes on the balance of cash and cash equivalents
held
in foreign currencies
|
690,302
|
(1,737,893
|
)
|
|||||||
Cash
and cash equivalents at the end of the financial
year
|
17(a)
|
|
15,446,552
|
12,892,061
|
1. |
Summary
of Significant Accounting
Policies
|
(i)
|
between
balance date and the date of this report, the Company has sold US$6.5
million ($8.5 million) of Subordinated Convertible Debentures as
further
described in Note 21;
|
(ii)
|
subsequent
to June 30, 2006 the Company closed an agreement to revise the terms
of
the convertible note as further described in Note 21. This included
the
rescheduling of capital repayments with two repayments of US$6.25
million
($8.56 million) in July 2007 and January 2008,
respectively;
|
(iii)
|
in
the event of a default under the terms of the convertible note the
Directors believe that they will be able to reach agreement on further
revisions to the terms of the convertible note without the debt being
called; and
|
(iv)
|
the
Directors believe that the Company has the capacity to raise additional
working capital either through the issue of additional equities or
new
debt issued to third parties, or a combination of debt and
equity.
|
(a)
|
Principles
of consolidation
|
(b)
|
Foreign
currency
|
Entity
|
Functional
currency
|
pSivida
Limited
|
Australian
dollar ($) to December 31, 2005
United
States dollar (US$) from January 1, 2006
|
pSiMedica
Limited
|
British
pound (£)
|
pSivida
Inc
|
United
States dollar (US$)
|
pSiOncology
Pte Ltd
|
Singapore
dollar (S$)
|
AION
Diagnostics Limited
|
Australian
dollar ($)
|
pSiNutria
Limited
|
British
pound (£)
|
(a)
|
assets
and liabilities for each balance sheet presented are translated at
the
closing rate at the date of that balance
sheet;
|
(b)
|
income
and expenses for each income statement are translated at exchange
rates at
the dates of the transactions; and
|
(c)
|
all
resulting exchange differences are recognized as a separate component
of
equity.
|
(c)
|
Cash
and cash equivalents
|
(d)
|
Financial
assets
|
(e)
|
Property,
plant and equipment
|
Leasehold improvements |
Lease
term
|
Plant and equipment |
3
years
|
(f)
|
Leases
|
(g)
|
Goodwill
|
(h)
|
Intangible
assets
|
·
|
the
technical feasibility of completing the intangible asset so that
it will
be available for use or sale;
|
·
|
the
intention to complete the intangible asset and use or sell
it;
|
·
|
the
ability to use or sell the intangible
asset;
|
·
|
how
the intangible asset will generate probable future economic
benefits;
|
·
|
the
availability of adequate technical, financial and other resources
to
complete the development and to use or sell the intangible asset;
and
|
·
|
the
ability to measure reliably the expenditure attributable to the intangible
asset during its development.
|
(i)
|
Trade
and other payables
|
(j)
|
Borrowings
|
(k)
|
Financial
instruments issued by the
Company
|
(l)
|
Provisions
|
(m)
|
Income
recognition
|
(n)
|
Goods
and services tax
|
·
|
for
receivables and payables which are recognized inclusive of GST;
and
|
·
|
where
the amount of GST incurred is not recoverable from the taxation authority,
it is recognized as part of the cost of acquisition of an asset or
as part
of an item of expense. GST incurred in respect of costs associated
with
share placements and non-tax deductible entertainment expenditure,
is not
recoverable from the taxation authority and GST incurred in respect
of
some stock exchange fees and registry expenses is only partially
recoverable from the taxation
authority.
|
(o) |
Income
tax
|
(p)
|
Employee
entitlements
|
§
|
wages
and salaries, non-monetary benefits, annual leave, sick leave and
other
leave entitlements; and
|
§
|
other
types of employee entitlements;
|
(q)
|
Impairment
of assets
|
(r)
|
Share-based
payments
|
(s)
|
Comparative
information
|
(t)
|
AASB
accounting standards issued but not yet in
effect
|
AASB
Amendment
|
Affected
Standards
|
Nature
of change to accounting policy
|
Application
date of standard
(reporting
period commences on or after)
|
Application
date for Group
|
|
||||
2005-1
|
AASB
139: Financial instruments: Recognition and Measurement
|
No
change to accounting policy required, therefore no impact.
|
January
1, 2006
|
July
1, 2006
|
2005-5
|
AASB139:
Financial instruments: Recognition and Measurement
|
No
change to accounting policy required, therefore no impact.
|
January
1, 2006
|
July
1, 2006
|
2005-6
|
AASB
3: Business Combinations
|
No
change to accounting policy required, therefore no impact.
|
January
1, 2006
|
July
1, 2006
|
2005-10
|
AASB
132: Financial Instruments: Disclosure and Presentation
AASB
101: Presentation of Financial Statements
AASB
114: Segment reporting
AASB
117: Leases
AASB
133: Earnings per Share
AASB
139: Financial instruments: Recognition and Measurement
UIG
4 Determining whether an Arrangement contains a lease
UIG
8 Scope of AASB 2
|
No
change to accounting policy required, therefore no impact.
|
January
1, 2007
|
July
1, 2007
|
New
standard
|
AASB
7 Financial Instruments: Disclosures
|
No
change to accounting policy required, therefore no impact.
|
January
1, 2007
|
July
1, 2007
|
·
|
AASB
1023: General Insurance Contracts
|
·
|
AASB
1038: Life Insurance Contracts
|
·
|
AASB
4: Insurance Contracts
|
·
|
UIG
5: Rights to Interests arising from Decommissioning, Restoration
and
Environmental Rehabilitation Funds
|
·
|
UIG
7: Applying the Restatement Approach under AASB129 Financial Reporting
in
Hyperinflationary Economies
|
2. |
Loss
from operations
|
Years
Ended June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
(a)
|
Revenue
|
Revenue
consisted of the following items:
|
|||||||
Royalties
|
460,926
|
-
|
|||||
Collaborative
research and development
|
863,143
|
-
|
|||||
Other
revenue
|
68,931
|
161,666
|
|||||
Total
revenue
|
1,393,000
|
161,666
|
(b)
|
Loss
before income tax
|
Loss
before income tax has been arrived at after crediting / (charging)
the
following gains / (losses):
|
|||||||
Interest
- other
|
574,582
|
667,310
|
|||||
Gain
/ (loss) on disposal of property, plant and equipment
|
6,051
|
(6,910
|
)
|
||||
Total
other income
|
580,633
|
660,400
|
|||||
|
|||||||
Net
foreign exchange gain / (loss)
|
724,811
|
(1,623,484
|
)
|
Years
Ended June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Loss
before income tax has been arrived at after charging the following
expenses:
|
|||||||
Finance
costs
|
|||||||
- interest
expense
|
1,073,051
|
-
|
|||||
- other
finance costs *
|
3,471,033
|
31,569
|
|||||
4,544,084
|
31,569
|
*
|
Other
finance costs in the 2006 year consist of amortization of the discount
and
issue costs components of the convertible note amounting to $2,972,608
and
penalty payments made in respect of the convertible note amounting
to
$498,425.
|
Depreciation
of non-current assets
|
305,350
|
43,939
|
|||||
Amortization
of non-current assets
|
9,316,078
|
6,070,231
|
|||||
|
|||||||
Research
and development costs immediately expensed
|
|||||||
- depreciation
of non-current assets
|
2,094,868
|
605,918
|
|||||
- other
research and development expenses
|
15,760,397
|
7,682,012
|
|||||
|
17,855,265
|
8,287,930
|
|||||
|
|||||||
Operating
lease rental payments
|
519,523
|
97,738
|
|||||
|
|||||||
Employee
benefit expense
|
|||||||
- equity
settled share-based payments
|
1,987,205
|
508,610
|
|||||
- defined
contribution plans
|
419,913
|
239,868
|
|||||
- other
employee benefits
|
3,015,174
|
800,139
|
|||||
5,422,292
|
1,548,617
|
3. |
Income
tax
|
(a)
|
Income
tax recognized in profit or
loss
|
Deferred
tax benefit relating to the origination and reversal of temporary
differences
|
(9,519,805
|
)
|
(3,620,891
|
)
|
|||
Total
tax benefit
|
(9,519,805
|
)
|
(3,620,891
|
)
|
Loss
from operations
|
(37,685,934
|
)
|
(20,813,923
|
)
|
|||
|
|||||||
Income
tax benefit calculated at 30% (2005: 30%)
|
(11,305,780
|
)
|
(6,244,177
|
)
|
|||
Non
deductible costs
|
4,875,945
|
2,091,624
|
|||||
Non
deductible share-based payments and charges
|
585,917
|
-
|
|||||
Unused
tax losses not recognized as deferred tax assets
|
-
|
291,621
|
|||||
Changes
in fair value of embedded derivative
|
(1,022,375
|
)
|
-
|
||||
Utilization
of prior year tax losses not previously recognized
|
(47,607
|
)
|
(22,520
|
)
|
|||
Recognition
of prior year tax losses not previously recognized
|
(1,431,366
|
)
|
-
|
||||
Movements
in other temporary differences not recognized as deferred tax
assets
|
(155,643
|
)
|
-
|
||||
Foreign
exchange movements during the year
|
(607,323
|
)
|
-
|
||||
Overseas
tax rates
|
(411,573
|
)
|
262,560
|
||||
Income
tax benefit
|
(9,519,805
|
)
|
(3,620,892
|
)
|
The
tax rate used in the above reconciliation is the corporate tax rate
of 30%
payable by Australian corporate entities on taxable profits under
Australian tax law. There has been no change in the corporate tax
rate
when compared with the previous reporting
period.
|
(b)
|
Current
tax assets and liabilities
|
Years
Ended June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Income
tax payable
|
-
|
-
|
(c)
|
Deferred
tax balances
|
Deferred
tax assets comprise:
|
|||||||
Tax
losses - revenue
|
28,446,347
|
5,611,096
|
|||||
Temporary
differences (provisions)
|
57,876
|
-
|
|||||
|
28,504,223
|
5,611,096
|
|||||
|
|||||||
Deferred
tax liabilities comprise:
|
|||||||
Patents
|
(47,115,784
|
)
|
(15,392,679
|
)
|
|||
In-process
research and development
|
(13,939,219
|
)
|
(341,073
|
)
|
|||
|
(61,055,003
|
)
|
(15,733,752
|
)
|
|||
|
|||||||
Net
deferred tax liability
|
(32,550,780
|
)
|
(10,122,656
|
)
|
|||
|
|||||||
Unrecognized
deferred tax assets:
|
|||||||
The
following deferred tax assets have not been brought to account as
assets:
|
|||||||
|
|||||||
Tax
losses - revenue
|
1,158,028
|
2,519,776
|
|||||
Research
and development tax credits
|
283,096
|
-
|
|||||
Capital
raising costs
|
76,540
|
-
|
|||||
Other
temporary differences
|
-
|
155,643
|
|||||
1,517,664
|
2,675,419
|
(d)
|
Movements
in deferred tax balances
|
Opening
balance
|
(10,122,656
|
)
|
-
|
||||
Profit
and loss credit / (charge)
|
9,519,805
|
3,620,892
|
|||||
Acquired
as part of business combination
|
(32,505,887
|
)
|
(13,743,548
|
)
|
|||
Foreign
exchange movements during the year
|
557,958
|
-
|
|||||
Closing
balance - net deferred tax liability
|
(32,550,780
|
)
|
(10,122,656
|
)
|
4.
|
Dividends
paid or provided for on ordinary
shares
|
5.
|
Trade
and other receivables
|
As
at June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Current
|
|||||||
Other
receivables (i)
|
1,001,486
|
709,418
|
|||||
1,001,486
|
709,418
|
(i)
|
Other
receivables include amounts outstanding for goods
& services tax (‘GST’) and value added tax (‘VAT’). These amounts are
non-interest bearing and have repayment terms applicable under the
relevant government authorities.
|
6.
|
Property,
plant and equipment
|
Plant
and equipment
|
Leasehold
improvements
|
Construction
in progress
|
Total
|
||||||||||
$
|
$
|
$
|
$
|
||||||||||
Gross
carrying amount
|
|||||||||||||
Balance
at July 1, 2004
|
1,360,533
|
14,214
|
-
|
1,374,747
|
|||||||||
Additions
|
1,358,690
|
146,978
|
1,904,551
|
3,410,219
|
|||||||||
Disposals
|
(112,724
|
)
|
-
|
-
|
(112,724
|
)
|
|||||||
Net
foreign currency exchange differences
|
(167,044
|
)
|
(5,393
|
)
|
(76,038
|
)
|
(248,475
|
)
|
|||||
Balance
at July 1, 2005
|
2,439,455
|
155,799
|
1,828,513
|
4,423,767
|
|||||||||
|
|||||||||||||
Additions
|
649,298
|
392,413
|
512,970
|
1,554,681
|
|||||||||
Disposals
|
(42,003
|
)
|
(3,706
|
)
|
-
|
(45,709
|
)
|
||||||
Acquisitions
through business combinations
|
609,572
|
14,510
|
-
|
624,082
|
|||||||||
Transfers
between asset categories
|
2,348,394
|
-
|
(2,348,394
|
)
|
-
|
||||||||
Net
foreign currency exchange differences
|
242,526
|
10,283
|
6,911
|
259,720
|
|||||||||
Balance
at June 30, 2006
|
6,247,242
|
569,299
|
-
|
6,816,541
|
|||||||||
|
|||||||||||||
Accumulated
depreciation
|
|||||||||||||
Balance
at July 1, 2004
|
(699,938
|
)
|
(5,110
|
)
|
-
|
(705,048
|
)
|
||||||
Disposals
|
105,814
|
-
|
-
|
105,814
|
|||||||||
Depreciation
expense
|
(605,910
|
)
|
(25,817
|
)
|
-
|
(631,727
|
)
|
||||||
Net
foreign currency exchange differences
|
80,118
|
739
|
-
|
80,857
|
|||||||||
Balance
at July 1, 2005
|
(1,119,916
|
)
|
(30,188
|
)
|
-
|
(1,150,104
|
)
|
||||||
|
|||||||||||||
Disposals
|
24,973
|
882
|
-
|
25,855
|
|||||||||
Depreciation
expense
|
(2,297,328
|
)
|
(102,890
|
)
|
-
|
(2,400,218
|
)
|
||||||
Net
foreign currency exchange differences
|
(147,923
|
)
|
(4,602
|
)
|
-
|
(152,525
|
)
|
||||||
Balance
at June 30, 2006
|
(3,540,194
|
)
|
(136,798
|
)
|
-
|
(3,676,992
|
)
|
||||||
|
|||||||||||||
Net
book value
|
|||||||||||||
As
at June 30, 2005
|
1,319,539
|
125,611
|
1,828,513
|
3,273,663
|
|||||||||
As
at June 30, 2006
|
2,707,048
|
432,501
|
-
|
3,139,549
|
7.
|
Goodwill
|
As
at June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Gross
carrying amount
|
|||||||
Balance
at beginning of year
|
23,305,698
|
-
|
|||||
Additional
amounts recognized from business combinations
|
30,406,123
|
23,305,698
|
|||||
Effects
of foreign currency exchange differences
|
(552,592
|
)
|
-
|
||||
Balance
at end of year
|
53,159,229
|
23,305,698
|
|||||
|
|||||||
Accumulated
impairment losses
|
|||||||
Balance
at beginning of year
|
-
|
-
|
|||||
Impairment
losses for year
|
-
|
-
|
|||||
Balance
at end of year
|
-
|
-
|
|||||
|
|||||||
Net
book value
|
|||||||
At
the end of the year
|
53,159,229
|
23,305,698
|
8.
|
Other
intangible assets
|
As
at June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Patents
and licenses
|
|||||||
Gross
carrying amount at beginning of year
|
58,056,474
|
11,447,452
|
|||||
Acquisitions
through business combinations
|
88,460,020
|
46,609,022
|
|||||
Net
foreign currency exchange differences
|
(2,685,469
|
)
|
-
|
||||
Gross
carrying amount at end of year
|
143,831,025
|
58,056,474
|
|||||
|
|||||||
Accumulated
amortization and impairment at beginning of year
|
(8,399,511
|
)
|
(2,329,280
|
)
|
|||
Amortization
expense (i)
|
(9,316,078
|
)
|
(6,070,231
|
)
|
|||
Net
foreign currency exchange differences
|
(248,434
|
)
|
-
|
||||
Accumulated
amortization and impairment at end of year
|
(17,964,023
|
)
|
(8,399,511
|
)
|
|||
|
|||||||
Net
book value at end of year
|
125,867,002
|
49,656,963
|
|||||
|
|||||||
In-process
research and development
|
|||||||
Gross
carrying amount at beginning of year
|
1,705,366
|
-
|
|||||
Acquisitions
through business combinations
|
34,281,686
|
1,705,366
|
|||||
Net
foreign currency exchange differences
|
253,053
|
-
|
|||||
Gross
carrying amount at end of year
|
36,240,105
|
1,705,366
|
|||||
|
|||||||
Accumulated
amortization and impairment at beginning of year
|
-
|
-
|
|||||
Amortization
expense (i)
|
-
|
-
|
|||||
Accumulated
amortization and impairment at end of year
|
-
|
-
|
|||||
|
|||||||
Net
book value at end of year
|
36,240,105
|
1,705,366
|
|||||
|
|||||||
Total
net book value at end of year
|
162,107,107
|
51,362,329
|
(i)
|
Amortization
expense is included in the line item ‘Selling, general and administrative’
in the statement of operations.
|
9.
|
Trade
and other payables
|
As
at June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Current
|
|||||||
Trade
payables (i)
|
1,655,637
|
806,047
|
|||||
Other
payables (i)
|
5,693,903
|
1,161,671
|
|||||
Accrued
interest
|
66,473
|
-
|
|||||
|
7,416,013
|
1,967,718
|
|||||
Current
- related party
|
|||||||
Amounts
payable to directors and their related parties
|
-
|
38,253
|
|||||
Amounts
payable to other related parties
|
-
|
11,849
|
|||||
|
-
|
50,102
|
|||||
|
|||||||
Total
trade and other payables at end of year
|
7,416,013
|
2,017,820
|
(i)
|
Trade
and other creditor
amounts represent liabilities for goods and services provided to
the Group
prior to the end of the financial year and which are unpaid. The
amounts
are unsecured and are usually paid within 30 days of
recognition.
|
10.
|
Borrowings
|
Current
- unsecured
|
|||||||
At
amortized cost
|
|||||||
Convertible
note (i)
|
11,219,697
|
-
|
|||||
|
|||||||
Non-Current
- unsecured
|
|||||||
At
amortized cost
|
|||||||
Convertible
note (i)
|
3,940,092
|
-
|
(i)
|
The
consolidated entity entered into a finance facility agreement with
Castlerigg Master Investments on 16 November 2005 to fund the expanded
development of pSivida’s platform technologies and ongoing working capital
requirements. The facility agreement contains a number of terms that
create a hybrid financial instrument being a loan host contract and
a
compound embedded derivative.
|
·
|
Face
value of US$15 million ($20.5
million)
|
·
|
Term
of 3 years
|
·
|
Interest
payable at an interest rate of 8% payable
quarterly
|
·
|
Convertible
into pSivida ADSs at an initial conversion price of US$7.10 per ADS
($0.95
per ordinary share)
|
11.
|
Other
financial liabilities
|
As
at June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Current
|
|||||||
Compound
embedded derivative - at fair value (i)
|
2,465,416
|
-
|
(i) |
The
compound
embedded derivative arose in connection with the finance facility
agreement with Castlerigg Master Investments. The facility agreement
contains a number of terms that create a hybrid financial instrument
consisting of a loan host contract and a compound embedded derivative.
In
accordance with the stated accounting policy, the embedded derivatives,
which include the conversion option and the holder’s redemption option,
are recognized separately from the host debt instrument. The value
of the
derivatives embedded in the loan has been determined at fair value
using a
Binomial Tree Model and changes over time are revalued on a marked
to
market basis through profit and
loss.
|
12.
|
Provisions
|
Notes
|
||||||||||
Provision
for employee entitlements
|
||||||||||
Balance
at beginning of year
|
29,879
|
-
|
||||||||
Net
arising and utilized during the year
|
2,596
|
29,879
|
||||||||
Acquisitions
through business combinations
|
25
|
161,234
|
-
|
|||||||
Net
foreign currency exchange differences
|
(789
|
)
|
-
|
|||||||
Balance
at end of year
|
192,920
|
29,879
|
||||||||
|
||||||||||
Current
|
19
|
192,920
|
29,879
|
13. |
Issued
capital
|
(a)
|
Issued
capital
|
As
at June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Ordinary
shares, fully paid
|
230,377,035
|
107,883,835
|
(b)
|
Movements
in share capital
|
2006
|
2005
|
2006
|
2005
|
|||||||||||||
Number
|
Number
|
$
|
$
|
|||||||||||||
Balance
at beginning of year
|
219,312,166
|
153,937,785
|
107,883,835
|
49,957,982
|
||||||||||||
Issued
during the year
|
||||||||||||||||
Share
placements
|
167,697,790
|
49,804,381
|
117,611,006
|
54,286,775
|
||||||||||||
Options
exercised
|
38,740
|
15,570,000
|
27,521
|
3,666,500
|
||||||||||||
Capital
raising pursuant to rights issue
|
10,515,811
|
-
|
6,309,487
|
-
|
||||||||||||
Forfeiture
of non-vested ADSs
|
(i)
|
|
(528,400
|
)
|
-
|
(291,174
|
)
|
-
|
||||||||
Amortization
of non-vested ADS
|
(i)
|
|
-
|
-
|
962,471
|
-
|
||||||||||
Share
and rights issue costs
|
-
|
-
|
(2,126,111
|
)
|
(27,422
|
)
|
||||||||||
Balance
at end of year
|
397,036,107
|
219,312,166
|
230,377,035
|
107,883,835
|
(i) |
Non-vested
ADSs were issued to employees of CDS as part of the acquisition of
CDS in
December 2005. Refer to Note 25 for further detail. The vesting of
the
non-vested ADSs is subject to the following
terms:
|
·
|
ADSs
vest on dates ranging from January 2007 to May 2008;
and
|
·
|
Non-vested
ADSs is forfeited on cessation of
employment.
|
(c)
|
Share
options and warrants
|
pSivida
Limited
|
Exercise
price
|
Expiry
date
|
Balance
at beginning of year
|
Granted
during the year
|
Exercised
during the year
|
Expired
during the year
|
Forfeited
during the year
|
Balance
at end of year
|
|||||||||||||||||
|
Number
|
Number
#
|
Number
#
|
Number
#
|
Number
|
Number
|
|||||||||||||||||||
Unlisted
options *
|
|
$0.61
|
12/31/07
|
4,375,000
|
-
|
-
|
-
|
-
|
4,375,000
|
||||||||||||||||
Unlisted
options
|
|
$1.09
|
8/5/08
|
2,050,000
|
-
|
-
|
-
|
-
|
2,050,000
|
||||||||||||||||
Unlisted
options *
|
|
$1.18
|
8/5/09
|
9,044,713
|
-
|
-
|
-
|
(110,041
|
)
|
8,934,672
|
|||||||||||||||
Unlisted
options *
|
|
$1.02
|
4/22/10
|
200,000
|
-
|
-
|
-
|
-
|
200,000
|
||||||||||||||||
Unlisted
options *
|
|
$0.80
|
12/31/08
|
115,000
|
-
|
-
|
-
|
-
|
115,000
|
||||||||||||||||
Unlisted
options *
|
|
$0.80
|
3/31/10
|
3,177,000
|
-
|
-
|
-
|
(345,500
|
)
|
2,831,500
|
|||||||||||||||
Unlisted
warrants over ADSs
|
|
US$1.25
|
9/9/08
|
-
|
1,330,000
|
-
|
-
|
-
|
1,330,000
|
||||||||||||||||
Unlisted
options *
|
|
$0.80
|
3/31/10
|
-
|
900,000
|
-
|
-
|
-
|
900,000
|
||||||||||||||||
Unlisted
warrants over ADSs
|
|
US$0.72
|
11/16/11
|
-
|
6,338,030
|
-
|
-
|
-
|
6,338,030
|
||||||||||||||||
Unlisted
options *
|
|
$0.92
|
9/30/10
|
-
|
400,000
|
-
|
-
|
-
|
400,000
|
||||||||||||||||
Unlisted
options over ADSs
|
|
US$3.22
|
6/12/06
|
-
|
70,460
|
-
|
(70,460
|
)
|
-
|
-
|
|||||||||||||||
Unlisted
options over ADSs
|
|
US$3.22
|
7/9/06
|
-
|
38,760
|
-
|
-
|
-
|
38,760
|
||||||||||||||||
Unlisted
options over ADSs
|
|
US$2.89
|
4/19/07
|
-
|
38,760
|
-
|
-
|
-
|
38,760
|
||||||||||||||||
Unlisted
options over ADSs
|
|
US$0.18
|
9/18/07
|
-
|
704,560
|
-
|
-
|
-
|
704,560
|
||||||||||||||||
Unlisted
options over ADSs
|
|
US$2.89
|
10/31/07
|
-
|
70,460
|
-
|
-
|
-
|
70,460
|
||||||||||||||||
Unlisted
options over ADSs
|
|
US$2.89
|
4/15/08
|
-
|
58,140
|
-
|
-
|
-
|
58,140
|
||||||||||||||||
Unlisted
options over ADSs
|
|
US$0.00
|
5/14/09
|
-
|
38,760
|
(38,740
|
)
|
-
|
-
|
20
|
|||||||||||||||
Unlisted
options over ADSs
|
|
US$0.23
|
8/25/09
|
-
|
352,280
|
-
|
-
|
-
|
352,280
|
||||||||||||||||
Unlisted
options over ADSs
|
|
US$0.34
|
11/12/09
|
-
|
352,280
|
-
|
-
|
-
|
352,280
|
||||||||||||||||
Unlisted
options *
|
|
$0.92
|
9/30/10
|
-
|
1,850,000
|
-
|
-
|
-
|
1,850,000
|
||||||||||||||||
18,961,713
|
12,542,490
|
(38,740
|
)
|
(70,460
|
)
|
(455,541
|
)
|
30,939,462
|
*
|
Options
issued pursuant to the Company’s Employee Share Option Plan
(‘ESOP’).
|
#
|
Numbers
of options and warrants over ADSs have been converted to equivalent
values
over ordinary shares to allow comparability with options over ordinary
shares.
|
AION
Diagnostics Consolidated Group
|
Exercise
price
|
Expiry
date
|
Balance
at beginning of year
|
Granted
during the year
|
Exercised
during the year
|
Cancelled
during the year
|
Forfeited
during the year
|
Balance
at end of year
|
|||||||||||||||||
|
Number
|
Number
|
Number
|
Number
|
Number
|
Number
|
|||||||||||||||||||
Unlisted
options *
|
|
$0.00
|
3/2/08
|
1,200,000
|
-
|
(1,000
|
)
|
(1,000
|
)
|
(260,000
|
)
|
938,000
|
|||||||||||||
Unlisted
options *
|
|
$0.00
|
3/2/08
|
-
|
261,000
|
-
|
-
|
-
|
261,000
|
||||||||||||||||
1,200,000
|
261,000
|
(1,000
|
)
|
(1,000
|
)
|
(260,000
|
)
|
1,199,000
|
*
|
Options
issued pursuant to the Company’s Employee Share Option Plan
(‘ESOP’).
|
pSivida
Limited
|
Exercise
price
|
Expiry
date
|
Balance
at beginning of year
|
Granted
during the year
|
Exercised
during the year
|
Forfeited
during the year
|
Balance
at end of year
|
|||||||||||||||
|
Number
|
Number
|
Number
|
Number
|
Number
|
|||||||||||||||||
Unlisted
options
|
|
$0.20
|
12/31/04
|
12,570,000
|
-
|
(12,570,000
|
)
|
-
|
-
|
|||||||||||||
Unlisted
options
|
|
$0.50
|
12/31/04
|
150,000
|
-
|
(150,000
|
)
|
-
|
-
|
|||||||||||||
Unlisted
options
|
|
$0.65
|
12/31/04
|
150,000
|
-
|
(150,000
|
)
|
-
|
-
|
|||||||||||||
Unlisted
options *
|
|
$0.40
|
12/31/04
|
2,200,000
|
-
|
(2,200,000
|
)
|
-
|
-
|
|||||||||||||
Unlisted
options *
|
|
$0.20
|
12/31/04
|
500,000
|
-
|
(500,000
|
)
|
-
|
-
|
|||||||||||||
Unlisted
options *
|
|
$0.61
|
12/31/07
|
4,395,000
|
-
|
-
|
(20,000
|
)
|
4,375,000
|
|||||||||||||
Unlisted
options
|
|
$1.09
|
8/5/08
|
-
|
2,050,000
|
-
|
-
|
2,050,000
|
||||||||||||||
Unlisted
options *
|
|
$1.18
|
8/5/09
|
-
|
9,114,537
|
-
|
(69,824
|
)
|
9,044,713
|
|||||||||||||
Unlisted
options *
|
|
$1.02
|
12/31/08
|
-
|
200,000
|
-
|
-
|
200,000
|
||||||||||||||
Unlisted
options *
|
|
$0.80
|
12/31/08
|
-
|
115,000
|
-
|
-
|
115,000
|
||||||||||||||
Unlisted
options *
|
|
$0.80
|
3/31/10
|
-
|
3,202,000
|
-
|
(25,000
|
)
|
3,177,000
|
|||||||||||||
|
19,965,000
|
14,681,537
|
(15,570,000
|
)
|
(114,824
|
)
|
18,961,713
|
AION
Diagnostics Consolidated Group
|
Exercise
price
|
Expiry
date
|
Balance
at beginning of year
|
Granted
during the year
|
Exercised
during the year
|
Forfeited
during the year
|
Balance
at end of year
|
|||||||||||||||
|
Number
|
Number
|
Number
|
Number
|
Number
|
|||||||||||||||||
Unlisted
options *
|
$
|
0.00
|
2/3/08
|
-
|
1,200,000
|
-
|
-
|
1,200,000
|
*
|
Options
issued pursuant to the Company’s Employee Share Option Plan
(‘ESOP’).
|
pSivida
Limited
|
AION
Diagnostics Consolidated Group
|
|||
Director
and employee
|
Consultant
|
CDS
Acquisition
|
Director
and employee
|
|
Number
of options over shares
|
3,150,000
|
-
|
-
|
261,000
|
Number
of options over ADSs
|
-
|
133,000
|
172,446
|
-
|
Black-Scholes
model fair value
|
$0.258
|
US$0.414
|
US$3.872
|
$0.290
|
Share
price at grant date
|
$0.722
|
US$5.798
|
US$5.169
|
$0.290
|
Exercise
price
|
$0.886
|
US$12.500
|
US$6.493
|
$0.00
|
Expected
volatility
|
55.0%
|
55.0%
|
55.0%
|
75.0%
|
Option
life
|
4.66
years
|
2.93
years
|
2.48
years
|
3.00
years
|
Expected
dividends
|
-
|
-
|
-
|
-
|
Risk-free
rate
|
5.257%
|
5.081%
|
5.350%
|
5.250%
|
(d)
|
Terms
and conditions of issued
capital
|
(e) |
Registration
rights agreements
|
14. |
Reserves
|
As
at June 30,
|
||||||||||
2006
|
2005
|
|||||||||
$
|
$
|
|||||||||
Foreign
currency translation
|
a
|
(3,023,955
|
)
|
(350,287
|
)
|
|||||
Option
premium reserve
|
b
|
2,687,025
|
292,828
|
|||||||
Employee
equity-settled benefits reserve
|
c
|
1,920,824
|
631,586
|
|||||||
|
1,583,894
|
574,127
|
(a)
|
Foreign
currency translation
reserve
|
Years
Ended June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Balance
at beginning of year
|
(350,287
|
)
|
-
|
||||
Loss
on translation of foreign controlled entities
|
(2,673,668
|
)
|
(350,287
|
)
|
|||
Balance
at end of year
|
(3,023,955
|
)
|
(350,287
|
)
|
(b)
|
Option
premium reserve
|
Years
Ended June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Balance
at beginning of year
|
292,828
|
-
|
|||||
Warrants
issued in connection with convertible note
|
1,706,592
|
-
|
|||||
Increase
on issue of options and warrants
|
715,111
|
292,828
|
|||||
Exercise
of options
|
(27,506
|
)
|
-
|
||||
Balance
at end of year
|
2,687,025
|
292,828
|
(c)
|
Employee
equity-settled benefits
reserve
|
Balance
at beginning of year
|
631,586
|
39,689
|
|||||
Share
based payments
|
1,289,238
|
591,897
|
|||||
Balance
at end of year
|
1,920,824
|
631,586
|
15.
|
Accumulated
deficit
|
(a)
|
Deficit
accumulated prior to development
stage
|
Balance
at end of year
|
(3,813,181
|
)
|
(3,813,181
|
)
|
(b)
|
Deficit
accumulated during development
stage
|
Balance
at beginning of year
|
(24,949,034
|
)
|
(8,155,198
|
)
|
|||
Net
loss attributable to members of the Company
|
(28,166,129
|
)
|
(16,793,836
|
)
|
|||
Balance
at end of year
|
(53,115,163
|
)
|
(24,949,034
|
)
|
16.
|
Minority
interest
|
Reconciliation
of minority interest in controlled
entities
|
Balance
at beginning of year
|
-
|
1,583,200
|
|||||
Share
of current year loss
|
-
|
(399,196
|
)
|
||||
Share
of foreign currency translation reserve
|
-
|
79,361
|
|||||
Effect
of change in shareholding
|
-
|
(1,263,365
|
)
|
||||
Balance
at end of year
|
-
|
-
|
17.
|
Notes
to the statement of cash
flows
|
(a)
|
Reconciliation
of cash and cash
equivalents
|
For
the purposes of the cash flow statement, cash and cash equivalents
includes cash on hand and in banks and investments in money market
instruments. Cash and cash equivalents at the end of the financial
year as
shown in the cash flow statement is reconciled to the related items
in the
balance sheet as follows:
|
Years
Ended June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Cash
on hand
|
3,922,626
|
1,637,560
|
|||||
Deposits
at call
|
11,523,926
|
11,254,501
|
|||||
15,446,552
|
12,892,061
|
(b)
|
Reconciliation
of loss for the period to net cash flows used in operating
activities
|
Loss
for the year
|
(28,166,129
|
)
|
(17,193,032
|
)
|
|||
Depreciation
|
2,400,195
|
631,727
|
|||||
Amortization
|
9,316,078
|
6,099,880
|
|||||
(Gain)
/ loss on disposal of property, plant and equipment
|
(6,051
|
)
|
6,910
|
||||
Share-based
compensation expense
|
1,953,056
|
591,897
|
|||||
Finance
costs
|
3,471,033
|
1,920
|
|||||
Deferred
income tax benefit
|
(9,519,805
|
)
|
(3,620,891
|
)
|
|||
Change
in fair value of derivative
|
(3,407,915
|
)
|
-
|
||||
Foreign
currency (gain) / loss
|
(724,659
|
)
|
1,623,484
|
||||
Changes
in operating assets and liabilities, net of effects from
acquisitions
|
|||||||
(Increase)
/ decrease in assets:
|
|||||||
Trade
and other receivables
|
279,244
|
(408,904
|
)
|
||||
Prepayments
|
(16,968
|
)
|
(290,102
|
)
|
|||
Increase
in liabilities:
|
|||||||
Trade
and other creditors
|
2,683,632
|
222,634
|
|||||
Provisions
|
2,596
|
29,879
|
|||||
Net
cash flows used in operating activities
|
(21,735,693
|
)
|
(12,304,598
|
)
|
(c)
|
Non-cash
financing and investing
activities
|
·
|
150,844,680
shares at a value of $0.71 each;
|
·
|
8,991,930
non-vested shares at a value of $0.71 each;
and
|
·
|
1,724,460
options valued using the Black-Scholes
model.
|
(d)
|
Business
combination transactions
|
Years
Ended June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Net
cash paid for acquisition of business
|
|||||||
Cash
consideration
|
114,319
|
-
|
|||||
Direct
acquisition costs paid on acquisition
|
4,147,202
|
||||||
Less
cash and cash equivalents balances acquired
|
(228,463
|
)
|
-
|
||||
|
4,033,058
|
-
|
Cost
of acquisition comprised of:
|
$
|
|||
·
Cash
|
4,323,622
|
|||
·
49,804,381
ordinary fully paid shares of pSivida
$1.09
per share
|
54,286,775
|
|||
·
638,537
share options in pSivida
|
292,828
|
|||
·
Direct
acquisition costs
|
321,342
|
|||
|
59,224,567
|
Years
Ended June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Net
cash paid for increased interest in subsidiary
|
|||||||
Cash
consideration
|
-
|
4,323,622
|
|||||
Direct
acquisition costs paid on acquisition
|
-
|
321,342
|
|||||
|
-
|
4,644,964
|
18.
|
Leases
|
(a)
|
Operating
leases
|
As
at June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Year
ended June 30, 2006
|
-
|
325,509
|
|||||
Year
ended June 30, 2007
|
893,143
|
119,423
|
|||||
Year
ended June 30, 2008
|
625,468
|
2,947
|
|||||
Year
ended June 30, 2009
|
584,923
|
-
|
|||||
Year
ended June 30, 2010
|
155,700
|
-
|
|||||
Year
ended June 30, 2011
|
103,800
|
-
|
|||||
Thereafter
|
-
|
-
|
|||||
|
2,363,034
|
447,879
|
19.
|
Employee
entitlements
|
Notes
|
||||||||||
Provision
for employee entitlements (current)
|
12
|
192,920
|
29,879
|
Number
|
Number
|
||||||
Number
of employees at end of financial year
|
55
|
36
|
pSivida
Limited
|
2006
|
2006
|
2005
|
2005
|
||||||||||||
Number
of
options
|
Weighted
average exercise price
$
|
Number
of
options
|
Weighted
average exercise price
$
|
|||||||||||||
Balance
at beginning of financial year
|
a
|
16,911,713
|
0.96
|
7,095,000
|
0.52
|
|||||||||||
Granted
during financial year
|
b
|
3,150,000
|
0.89
|
12,621,537
|
1.08
|
|||||||||||
Exercised
during financial year
|
c
|
-
|
(1,050,000
|
)
|
0.28
|
|||||||||||
Transferred
during financial year
|
d
|
-
|
(1,650,000
|
)
|
0.38
|
|||||||||||
Forfeited
during financial year
|
e
|
(455,541
|
)
|
0.89
|
(104,824
|
)
|
0.98
|
|||||||||
Balance
at end of financial year
|
f
|
19,606,172
|
0.95
|
16,911,713
|
0.96
|
|||||||||||
Exercisable
at end of financial year
|
17,831,172
|
0.87
|
13,744,713
|
0.81
|
Range
of exercise price
|
Number
of options
|
Weighted
average exercise price
|
|||||
$0.50
to $0.75
|
4,375,000
|
$
|
0.61
|
||||
$0.75
to $1.00
|
6,096,500
|
$
|
0.84
|
||||
$1.00
to $1.25
|
9,134,672
|
$
|
1.18
|
||||
|
19,606,172
|
(a) |
Balance
at beginning of financial year
|
Options
- series
2006
|
Number
|
Grant
date
|
Vesting
date
|
Expiry
date
|
Exercise
price
$
|
|||||||||||
Issued
October 21, 2003
|
250,000
|
10/21/03
|
10/21/03
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
250,000
|
10/21/03
|
7/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
2,325,000
|
10/21/03
|
4/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
350,000
|
10/21/03
|
1/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
400,000
|
10/21/03
|
10/21/03
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
400,000
|
10/21/03
|
10/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
400,000
|
10/21/03
|
10/21/05
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
August 5, 2004
|
175,000
|
8/5/04
|
8/5/04
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
August 5, 2004
|
40,000
|
8/5/04
|
8/5/05
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
August 5, 2004
|
8,829,713
|
8/5/04
|
8/5/04
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
April 22, 2005
|
200,000
|
4/22/05
|
4/22/05
|
4/22/10
|
$
|
1.02
|
||||||||||
Issued
April 22, 2005
|
115,000
|
4/22/05
|
4/22/05
|
12/31/08
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
50,000
|
4/22/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
450,000
|
4/22/05
|
4/22/05
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
2,227,000
|
4/22/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
450,000
|
4/22/05
|
4/22/07
|
3/31/10
|
$
|
0.80
|
||||||||||
|
16,911,713
|
(b) |
Granted
during financial year
|
Options
- series
2006
|
Number
|
Grant
date
|
Vesting
date
|
Expiry
date
|
Exercise
price
$
|
|||||||||||
Issued
November 15, 2005
|
900,000
|
11/15/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
November 16, 2005
|
400,000
|
11/16/05
|
11/16/06
|
9/30/10
|
$
|
0.92
|
||||||||||
Issued
December 30, 2005
|
875,000
|
12/30/05
|
12/30/05
|
9/30/10
|
$
|
0.92
|
||||||||||
Issued
December 30, 2005
|
487,500
|
12/30/05
|
12/30/06
|
9/30/10
|
$
|
0.92
|
||||||||||
Issued
December 30, 2005
|
487,500
|
12/30/05
|
12/30/07
|
9/30/10
|
$
|
0.92
|
||||||||||
|
3,150,000
|
Options
- series
2005
|
Number
|
Grant
date
|
Vesting
date
|
Expiry
date
|
Exercise
price
$
|
|||||||||||
Issued
August 5, 2004
|
175,000
|
8/5/04
|
8/5/04
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
August 5, 2004
|
50,000
|
8/5/04
|
8/5/05
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
August 5, 2004
|
8,889,537
|
8/5/04
|
8/5/04
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
April 22, 2005
|
200,000
|
4/22/05
|
4/22/05
|
4/22/10
|
$
|
1.02
|
||||||||||
Issued
April 22, 2005
|
115,000
|
4/22/05
|
4/22/05
|
12/31/08
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
40,000
|
4/22/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
450,000
|
4/22/05
|
4/22/05
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
2,252,000
|
4/22/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
450,000
|
4/22/05
|
4/22/07
|
3/31/10
|
$
|
0.80
|
||||||||||
|
12,621,537
|
(c) |
Exercised
during financial year
|
Options
- series
2005
|
Number
|
Grant
date
|
Vesting
date
|
Expiry
date
|
Exercise
price
$
|
|||||||||||
Issued
December 31, 2001
|
(550,000
|
)
|
12/31/01
|
10/13/03
|
12/31/04
|
$
|
0.40
|
|||||||||
Issued
November 1, 2002
|
(500,000
|
)
|
11/1/02
|
11/1/03
|
12/31/04
|
$
|
0.20
|
|||||||||
|
(1,050,000
|
)
|
(d) |
Transferred
during financial year
|
Options
- series
2005
|
Number
|
Grant
date
|
Vesting
date
|
Expiry
date
|
Exercise
price
$
|
|||||||||||
Issued
December 31, 2001
|
(1,650,000
|
)
|
12/31/01
|
10/13/03
|
12/31/04
|
$
|
0.40
|
(e) |
Forfeited
during financial year
|
Options
- series
2006
|
Number
|
Grant
date
|
Vesting
date
|
Expiry
date
|
Exercise
price
$
|
|||||||||||
Issued
August 5, 2004
|
(100,041
|
)
|
8/5/04
|
8/5/04
|
8/5/09
|
$
|
1.18
|
|||||||||
Issued
August 5, 2004
|
(10,000
|
)
|
8/5/04
|
8/5/05
|
8/5/09
|
$
|
1.18
|
|||||||||
Issued
April 22, 2005
|
(50,000
|
)
|
4/22/05
|
4/22/05
|
3/31/10
|
$
|
0.80
|
|||||||||
Issued
April 22, 2005
|
(245,500
|
)
|
4/22/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
|||||||||
Issued
April 22, 2005
|
(50,000
|
)
|
4/22/05
|
4/22/07
|
3/31/10
|
$
|
0.80
|
|||||||||
(455,541
|
)
|
Options
- series
2005
|
Number
|
Grant
date
|
Vesting
date
|
Expiry
date
|
Exercise
price
$
|
|||||||||||
Issued
October 21, 2003
|
(20,000
|
)
|
10/21/03
|
4/21/04
|
12/31/07
|
$
|
0.61
|
|||||||||
Issued
August 5, 2004
|
(59,824
|
)
|
8/5/04
|
8/5/04
|
8/5/09
|
$
|
1.18
|
|||||||||
Issued
April 22, 2005
|
(25,000
|
)
|
4/22/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
|||||||||
|
(104,824
|
)
|
(f) |
Balance
at end of financial year
|
Options
- series
2006
|
Number
|
Grant
date
|
Vesting
date
|
Expiry
date
|
Exercise
price
$
|
|||||||||||
Issued
October 21, 2003
|
250,000
|
10/21/03
|
10/21/03
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
250,000
|
10/21/03
|
7/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
2,325,000
|
10/21/03
|
4/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
350,000
|
10/21/03
|
1/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
400,000
|
10/21/03
|
10/21/03
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
400,000
|
10/21/03
|
10/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
400,000
|
10/21/03
|
10/21/05
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
August 5, 2004
|
175,000
|
8/5/04
|
8/5/04
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
August 5, 2004
|
30,000
|
8/5/04
|
8/5/05
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
August 5, 2004
|
8,729,672
|
8/5/04
|
8/5/04
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
April 22, 2005
|
200,000
|
4/22/05
|
4/22/05
|
4/22/10
|
$
|
1.02
|
||||||||||
Issued
April 22, 2005
|
115,000
|
4/22/05
|
4/22/05
|
12/31/08
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
50,000
|
4/22/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
400,000
|
4/22/05
|
4/22/05
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
1,981,500
|
4/22/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
400,000
|
4/22/05
|
4/22/07
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
November 15, 2005
|
900,000
|
11/15/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
November 16, 2005
|
400,000
|
11/16/05
|
11/16/06
|
9/30/10
|
$
|
0.92
|
||||||||||
Issued
December 30, 2005
|
875,000
|
12/30/05
|
12/30/05
|
9/30/10
|
$
|
0.92
|
||||||||||
Issued
December 30, 2005
|
487,500
|
12/30/05
|
12/30/06
|
9/30/10
|
$
|
0.92
|
||||||||||
Issued
December 30, 2005
|
487,500
|
12/30/05
|
12/30/07
|
9/30/10
|
$
|
0.92
|
||||||||||
19,606,172
|
Options
- series
2005
|
Number
|
Grant
date
|
Vesting
date
|
Expiry
date
|
Exercise
price
$
|
|||||||||||
Issued
October 21, 2003
|
250,000
|
10/21/03
|
10/21/03
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
250,000
|
10/21/03
|
7/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
2,325,000
|
10/21/03
|
4/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
350,000
|
10/21/03
|
1/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
400,000
|
10/21/03
|
10/21/03
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
400,000
|
10/21/03
|
10/21/04
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
October 21, 2003
|
400,000
|
10/21/03
|
10/21/05
|
12/31/07
|
$
|
0.61
|
||||||||||
Issued
August 5, 2004
|
175,000
|
8/5/04
|
8/5/04
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
August 5, 2004
|
40,000
|
8/5/04
|
8/5/05
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
August 5, 2004
|
8,829,713
|
8/5/04
|
8/5/04
|
8/5/09
|
$
|
1.18
|
||||||||||
Issued
April 22, 2005
|
200,000
|
4/22/05
|
4/22/05
|
4/22/10
|
$
|
1.02
|
||||||||||
Issued
April 22, 2005
|
115,000
|
4/22/05
|
4/22/05
|
12/31/08
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
50,000
|
4/22/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
450,000
|
4/22/05
|
4/22/05
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
2,227,000
|
4/22/05
|
4/22/06
|
3/31/10
|
$
|
0.80
|
||||||||||
Issued
April 22, 2005
|
450,000
|
4/22/05
|
4/22/07
|
3/31/10
|
$
|
0.80
|
||||||||||
|
16,911,713
|
AION
Diagnostics Consolidated Group
|
2006
|
2006
|
2005
|
2005
|
|||||||||
|
Number
of options
|
Weighted
average exercise price
$
|
Number
of options
|
Weighted
average exercise price
$
|
|||||||||
Balance
at beginning of financial year
|
1,200,000
|
0.00
|
-
|
0.00
|
|||||||||
Granted
during financial year
|
261,000
|
0.00
|
1,200,000
|
0.00
|
|||||||||
Exercised
during financial year
|
(1,000
|
)
|
0.00
|
-
|
0.00
|
||||||||
Forfeited
during financial year
|
(260,000
|
)
|
0.00
|
-
|
0.00
|
||||||||
Cancelled
during financial year
|
(1,000
|
)
|
0.00
|
-
|
0.00
|
||||||||
Balance
at end of financial year
|
1,199,000
|
0.00
|
1,200,000
|
0.00
|
|||||||||
Exercisable
at end of financial year
|
479,524
|
0.00
|
-
|
-
|
Options
- series
2006
|
Number
|
Grant
date
|
Vesting
date
|
Expiry
date
|
Exercise
price
$
|
|||||||||||
Issued
3 February 2005
|
719,476
|
3/2/05
|
30/9/06
|
3/2/08
|
$
|
0.00
|
||||||||||
Issued
3 February 2005
|
479,524
|
3/2/05
|
13/10/05
|
3/2/08
|
$
|
0.00
|
||||||||||
1,199,000
|
20.
|
Contingent
liabilities
|
21.
|
Subsequent
events
|
22.
|
Loss
per share
|
As
at June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Net
loss attributable to ordinary equity holders of the parent
|
(28,166,129
|
)
|
(16,793,836
|
)
|
Number
|
Number
|
||||||
Weighted
average number of ordinary shares for basic loss per share
|
305,882,956
|
207,802,540
|
|||||
Effect
of dilution:
|
|||||||
Share
options
|
-
|
-
|
|||||
Weighted
average number of ordinary shares for diluted loss per
share
|
305,882,956
|
207,802,540
|
Equity
securities
|
Number
of securities
|
Potential
ordinary shares
|
|||||
Options
over ordinary shares
|
21,656,172
|
21,656,172
|
|||||
Options
over ADSs
|
161,526
|
1,615,260
|
|||||
Warrants
over ADSs
|
766,803
|
7,668,030
|
|||||
Convertible
note
|
2,112,676
|
21,126,760
|
|||||
52,066,222
|
Equity
securities
|
Number
of securities
|
Potential
ordinary shares
|
|||||
Additional
warrants in relation to convertible notes
|
8,625,000
|
86,250,000
|
|||||
Amendment
to convertible note
|
4,137,324
|
41,373,240
|
|||||
New
convertible note
|
3,250,000
|
32,500,000
|
|||||
160,123,240
|
23.
|
Director,
executive and other related party
disclosures
|
(a)
|
Equity
interests in related
parties
|
Country
of incorporation
|
2006
|
2005
|
|
%
|
%
|
||
Parent
entity
|
|||
pSivida
Limited
|
Australia
|
||
Subsidiaries
|
|||
pSiMedica
Limited
|
UK
|
100
|
100
|
pSivida
Inc
|
US
|
100
|
100
|
pSiOncology
Pte Ltd (i)
|
Singapore
|
100
|
100
|
AION
Diagnostics Limited (i)
|
Australia
|
100
|
100
|
AION
Diagnostics Inc (ii)
|
US
|
100
|
-
|
pSivida
UK Limited (i)
|
UK
|
100
|
100
|
pSiNutria
Limited (ii)
|
Australia
|
100
|
-
|
pSiNutria
UK Limited (i) (ii)
|
UK
|
100
|
-
|
(i)
|
These
subsidiaries are not directly held by pSivida
Limited.
|
(ii)
|
These
companies were incorporated during the year ended June 30, 2006.
|
(b)
|
Details
of key management
personnel
|
·
|
Dr
Roger Brimblecombe - Executive
Chairman
|
·
|
Mr
Gavin Rezos - Managing Director (resigned July 31,
2006)
|
·
|
Dr
Paul Ashton - Director, Strategy (appointed December 30,
2005)
|
·
|
Mr
Stephen Lake - Non-Executive
Director
|
·
|
Dr
David Mazzo - Non-Executive Director (appointed July 25,
2005)
|
·
|
Mr
Michael Rogers - Non-Executive Director (appointed July 27,
2005)
|
·
|
Ms
Heather Zampatti - Non-Executive Director (appointed January 11,
2006,
resigned August 28, 2006)
|
·
|
Dr
Roger Aston - Director, Strategy (resigned November 15,
2005)
|
·
|
Ms
Alison Ledger - Non-Executive Director (resigned January 11,
2006)
|
·
|
Dr
Mark Parry-Billings - Director, Europe, pSiMedica
Limited
|
·
|
Mr
Aaron Finlay - Company Secretary, Former Chief Financial
Officer
|
·
|
Dr
Anna Kluczewska - Managing Director, AION Diagnostics
Limited
|
·
|
Prof
Leigh Canham - Chief Scientific Officer, pSiMedica
Limited
|
·
|
Mr
Steve Connor - Director of Development, pSiMedica
Limited
|
·
|
Dr
Jill Ogden - Commercial Director, pSiMedica
Limited
|
·
|
Ms
Lori Freedman - Company Secretary, Vice President of Corporate Affairs,
General Counsel (appointed
May 23, 2006)
|
·
|
Mr
Michael Soja - Vice President, Finance and Chief Financial Officer
(appointed
May 23, 2006)
|
(c)
|
Compensation
of key management
personnel
|
(i)
|
Compensation
policy
|
(a)
|
Short-term
benefits - salary / fees, bonuses and other
benefits;
|
(b)
|
Post-employment
benefits - including superannuation;
and
|
(c)
|
Share-based
payments - share options granted under the Employee Share Option
Plan as
disclosed in Note 19 to the financial
statements.
|
(ii)
|
Key
management personnel
compensation
|
The
aggregate compensation of the key management personnel of the consolidated
entity and the company is set out
below:
|
Years
Ended June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Short-term
|
3,142,567
|
2,029,768
|
|||||
Post
employment
|
161,141
|
99,810
|
|||||
Other
long-term
|
-
|
-
|
|||||
Termination
benefit
|
-
|
-
|
|||||
Share-based
payment
|
943,333
|
3,643,681
|
|||||
4,247,041
|
5,773,259
|
2006
|
Short-term
benefits
|
Post-employment
|
Share-based
payments
|
Total
|
Proportion
related to performance
|
|||||||||||||||||
Salary
and fees
|
Bonus
#
(i)
|
Other
benefits
|
Superannuation
|
Options
*
(ii)
|
||||||||||||||||||
$
|
$
|
$
|
$
|
$
|
$
|
%
|
||||||||||||||||
Directors
|
||||||||||||||||||||||
Dr
R
Brimblecombe
|
223,218
|
-
|
-
|
-
|
101,898
|
325,116
|
31.3
|
|||||||||||||||
Mr
G
Rezos
|
467,437
|
257,000
|
6,366
|
14,648
|
306,681
|
1,052,132
|
53.9
|
|||||||||||||||
Dr
P
Ashton
|
184,159
|
-
|
4,776
|
5,542
|
48,195
|
242,672
|
19.9
|
|||||||||||||||
Mr
S
Lake
|
25,000
|
-
|
-
|
-
|
-
|
25,000
|
-
|
|||||||||||||||
Dr
D
Mazzo
|
32,102
|
-
|
-
|
-
|
32,852
|
64,954
|
-
|
|||||||||||||||
Mr
M
Rogers
|
37,213
|
-
|
-
|
-
|
32,852
|
70,065
|
-
|
|||||||||||||||
Ms
H
Zampatti
|
15,613
|
-
|
-
|
1,405
|
-
|
17,018
|
-
|
|||||||||||||||
Dr
R
Aston
|
304,121
|
26,600
|
-
|
4,560
|
-
|
335,281
|
7.9
|
|||||||||||||||
Ms
A
Ledger
|
15,806
|
-
|
-
|
1,423
|
-
|
17,229
|
-
|
|||||||||||||||
Total
|
1,304,669
|
283,600
|
11,142
|
27,578
|
522,478
|
2,149,467
|
||||||||||||||||
Other
key management personnel
|
||||||||||||||||||||||
Dr
M
Parry-Billings
|
303,059
|
-
|
7,703
|
36,367
|
144,238
|
491,367
|
29.4
|
|||||||||||||||
Mr
A
Finlay
|
253,215
|
60,000
|
8,380
|
28,189
|
96,979
|
446,763
|
35.6
|
|||||||||||||||
Dr
A
Kluczewska
|
250,000
|
-
|
4,774
|
-
|
49,603
|
304,377
|
16.6
|
|||||||||||||||
Prof
L Canham
|
197,476
|
-
|
6,389
|
22,498
|
28,083
|
254,446
|
11.0
|
|||||||||||||||
Mr
S
Connor
|
182,444
|
-
|
8,608
|
21,893
|
32,033
|
244,978
|
13.1
|
|||||||||||||||
Dr
J
Ogden
|
171,449
|
-
|
5,233
|
20,574
|
24,133
|
221,389
|
10.9
|
|||||||||||||||
Ms
L
Freedman
|
40,099
|
-
|
2,114
|
2,021
|
22,893
|
67,127
|
34.1
|
|||||||||||||||
Mr
M
Soja
|
40,099
|
-
|
2,114
|
2,021
|
22,893
|
67,127
|
34.1
|
|||||||||||||||
Total
|
1,437,841
|
60,000
|
45,315
|
133,563
|
420,855
|
2,097,574
|
||||||||||||||||
Total
|
2,742,510
|
343,600
|
56,457
|
161,141
|
943,333
|
4,247,041
|
*
|
These
options had no intrinsic value at the date of
issue.
|
(i)
|
Bonuses
were paid in October 2005 to executive directors and staff as short
term
incentives following the achievement of key milestones following
a
recommendation from the Company’s Remuneration Committee. No other bonuses
have been paid by the Company up to the date of issuing this
report.
|
(ii)
|
A
total of 900,000 options were issued to directors and employees in
November 2005. The options are exercisable at $0.80, being a 10%
premium
to the share price at the time that the options were announced (subject
to
shareholder approval) in April 2005. The options are subject to varying
vesting conditions and expire on March 31,
2010.
|
A
total of 400,000 options were issued to directors and employees in
November 2005. The options are exercisable at $0.92, being a 10%
premium
to the 10 day weighted average share price prior to the date of the
Notice
of Meeting to approve the grant of the options. The options are subject
to
varying vesting conditions and expire on September 30,
2010.
|
A
total of 1,850,000 options were issued to directors and employees
in
December 2005. The options are exercisable at $0.92, being a 10%
premium
to the 10 day weighted average share price prior to the date of the
Notice
of Meeting to approve the grant of the options. The options are subject
to
varying vesting and performance conditions and expire on September
30,
2010. Of these options issued to directors and employees the following
have performance conditions as detailed
below:
|
Dr
P
Ashton
|
500,000
|
Subject
to 250,000 vesting in 12 months and 250,000 vesting in 24 months
from the
date of grant. The Company has the right to require additional performance
conditions to be met in relation to the vesting of these options
as
advised by management and applied by the Board and Remuneration
Committee.
|
||
Ms
L
Freedman
|
237,500
|
Subject
to 118,750 vesting in 12 months and 118,750 vesting in 24 months
from the
date of grant. The Company has the right to require additional performance
conditions to be met in relation to the vesting of these options
as
advised by management and applied by the Board and Remuneration
Committee.
|
||
Mr
M
Soja
|
237,500
|
Subject
to 118,750 vesting in 12 months and 118,750 vesting in 24 months
from the
date of grant. The Company has the right to require additional performance
conditions to be met in relation to the vesting of these options
as
advised by management and applied by the Board and Remuneration
Committee.
|
2005
|
Short-term
|
Post
Employment
|
Share-based
payment
|
Total
|
Proportion
related to performance
|
|||||||||||||||||
|
Salary
and fees
|
Bonus
(i)
|
Other
Benefits
|
Superannuation
|
Options
*
(ii)
|
|||||||||||||||||
|
$
|
$
|
$
|
$
|
$
|
$
|
%
|
|||||||||||||||
Directors
|
||||||||||||||||||||||
Dr
R
Brimblecombe
|
224,459
|
25,000
|
-
|
-
|
229,296
|
478,755
|
47.9
|
|||||||||||||||
Mr
G
Rezos
|
348,062
|
75,000
|
-
|
10,905
|
1,361,127
|
1,795,094
|
80.0
|
|||||||||||||||
Dr
R
Aston
|
315,683
|
25,000
|
1,189
|
8,438
|
558,592
|
908,902
|
64.2
|
|||||||||||||||
Mr
S
Lake
|
22,917
|
-
|
-
|
-
|
91,718
|
114,635
|
-
|
|||||||||||||||
Ms
A
Ledger
|
27,500
|
-
|
-
|
2,475
|
91,718
|
121,693
|
-
|
|||||||||||||||
Mrs
N Donovan
|
2,083
|
-
|
-
|
188
|
-
|
2,271
|
-
|
|||||||||||||||
Total
|
940,704
|
125,000
|
1,189
|
22,006
|
2,332,451
|
3,421,350
|
||||||||||||||||
|
||||||||||||||||||||||
Other
key management personnel
|
||||||||||||||||||||||
Prof
L Canham
|
193,780
|
-
|
6,056
|
22,553
|
353,524
|
575,913
|
61.4
|
|||||||||||||||
Mr
A
Finlay
|
144,572
|
32,500
|
-
|
13,135
|
370,396
|
560,603
|
71.9
|
|||||||||||||||
Dr
A
Kluczewska
|
208,333
|
10,000
|
-
|
-
|
299,808
|
518,141
|
59.8
|
|||||||||||||||
Mr
S
Connor
|
181,146
|
-
|
10,612
|
21,738
|
143,751
|
357,247
|
40.2
|
|||||||||||||||
Dr
J
Ogden
|
169,816
|
-
|
6,060
|
20,378
|
143,751
|
340,005
|
42.3
|
|||||||||||||||
Total
|
897,647
|
42,500
|
22,728
|
77,804
|
1,311,230
|
2,351,909
|
||||||||||||||||
|
||||||||||||||||||||||
Total
|
1,838,351
|
167,500
|
23,917
|
99,810
|
3,643,681
|
5,773,259
|
*
|
These
options had no intrinsic value at the date of
issue.
|
(i)
|
Bonuses
were paid in April 2005 to executive directors and staff as short
term
incentives following the achievement of key milestones following
a
recommendation from the Company’s Remuneration
Committee.
|
(ii)
|
During
the year ended June 30, 2005 options were granted to directors and
specified executives in August 2004 in respect of the pSiMedica
acquisition and April 2005 in respect of annual performance reviews,
pursuant to the Company’s Employee Share Option Plan, which have been
included as equity options remuneration above. These options have
been
valued using the Black Scholes Option Valuation Model, which takes
into
account time value and the volatility of the stock
price.
|
A
total of 8,251,000 options were issued to directors and employees
in
August 2004. The options are exercisable at $1.18, being an 8% premium
to
the share price at the time of the grant, and may be exercised between
the
date of grant and expiry on August 5,
2009.
|
A
total of 3,152,000 options were issued to employees in April 2005.
The
options are exercisable at $0.80, being a 10% premium to the share
price
at the time of the grant. The options are subject to varying vesting
and
performance conditions and expire on March 31,
2010.
|
(d)
|
Contracts
for services of directors and key management
personnel
|
(e)
|
Compensation
options: granted and vested during the
year
|
2006
|
Terms
and conditions for each grant
|
||||||||||||||||||||||||
|
Vested
|
Granted
|
Grant
date
|
Value
per option at grant date **
|
Value
of underlying share at grant date
|
Exercise
price per share
|
Vesting
date
|
Expiry
date
|
|||||||||||||||||
|
Number
|
Number
|
$
|
$
|
$
|
|
|
||||||||||||||||||
Directors
|
|||||||||||||||||||||||||
Dr
R
Brimblecombe
|
300,000
75,000
|
300,000
75,000
|
15
Nov05
30
Dec05
|
$
$
|
0.283
0.229
|
$
$
|
0.745
0.71
|
$
$
|
0.80
0.92
|
22
Apr 06
30
Dec 05
|
31
Mar 10
30
Sep 10
|
||||||||||||||
Mr
G
Rezos
|
600,000
600,000
|
600,000
600,000
|
15
Nov05
30
Dec05
|
$
$
|
0.283
0.229
|
$
$
|
0.745
0.71
|
$
$
|
0.80
0.92
|
22
Apr 06
30
Dec 05
|
31
Mar 10
30
Sep 10
|
||||||||||||||
Dr
D
Mazzo
|
-
|
200,000
|
16
Nov05
|
$
|
0.264
|
$
|
0.725
|
$
|
0.92
|
16
Nov 06
|
30
Sep 10
|
||||||||||||||
Mr
M
Rogers
|
-
|
200,000
|
16
Nov05
|
$
|
0.264
|
$
|
0.725
|
$
|
0.92
|
16
Nov 06
|
30
Sep 10
|
||||||||||||||
Dr
P
Ashton
|
-
-
|
*
250,000
*
250,000
|
30
Dec05
30
Dec05
|
$
$
|
0.250
0.270
|
$
$
|
0.71
0.71
|
$
$
|
0.92
0.92
|
30
Dec 06
30
Dec 07
|
30
Sep 10
30
Sep 10
|
|
|||||||||||||
Total
|
1,575,000
|
2,475,000
|
|
||||||||||||||||||||||
Other
key management personnel
|
|||||||||||||||||||||||||
Dr
M
Parry-Billings
|
320,000
|
-
|
22
Apr05
|
$
|
0.316
|
$
|
0.75
|
$
|
0.80
|
22
Apr 06
|
31
Mar 10
|
||||||||||||||
Mr
A
Finlay
|
200,000
200,000
|
-
200,000
|
22
Apr05
30
Dec05
|
$
$
|
0.316
0.229
|
$
$
|
0.75
0.71
|
$
$
|
0.80
0.92
|
22
Apr 06
30
Dec 06
|
31
Mar 10
30
Sep 10
|
||||||||||||||
Dr
A
Kluczewska
|
400,000
125,000
|
-
-
|
21
Oct03
22
Apr05
|
$
$
|
0.287
0.316
|
$
$
|
0.58
0.75
|
$
$
|
0.61
0.80
|
31
Dec 05
22
Apr 06
|
31
Dec 07
31
Mar 10
|
||||||||||||||
Prof
L Canham
|
112,500
|
-
|
22
Apr05
|
$
|
0.316
|
$
|
0.75
|
$
|
0.80
|
22
Apr 06
|
31
Mar 10
|
||||||||||||||
Mr
S
Connor
|
125,000
|
-
|
22
Apr05
|
$
|
0.316
|
$
|
0.75
|
$
|
0.80
|
22
Apr 06
|
31
Mar 10
|
||||||||||||||
Dr
J
Ogden
|
100,000
|
-
|
22
Apr05
|
$
|
0.316
|
$
|
0.75
|
$
|
0.80
|
22
Apr 06
|
31
Mar 10
|
||||||||||||||
Ms
L
Freedman
|
-
-
|
*
118,750
*
118,750
|
30
Dec05
30
Dec05
|
$
$
|
0.250
0.270
|
$
$
|
0.71
0.71
|
$
$
|
0.92
0.92
|
30
Dec 06
30
Dec 07
|
30
Sep 10
30
Sep 10
|
||||||||||||||
Mr
M
Soja
|
-
-
|
*
118,750
*
118,750
|
30
Dec05
30
Dec05
|
$
$
|
0.250
0.270
|
$
$
|
0.71
0.71
|
$
$
|
0.92
0.92
|
30
Dec 06
30
Dec 07
|
30
Sep 10
30
Sep 10
|
||||||||||||||
Total
|
1,582,500
|
675,000
|
Share
options issued by AION Diagnostics
Limited
|
2006
|
Terms
and conditions for each grant
|
||||||||||||||||||||||||
|
Vested
|
Granted
|
Grant
date
|
Value
per option at grant date **
|
Value
of underlying share at grant date
|
Exercise
price per share
|
Vesting
date
|
Expiry
date
|
|||||||||||||||||
|
Number
|
Number
|
$
|
$
|
$
|
|
|||||||||||||||||||
Directors
|
|||||||||||||||||||||||||
Dr
R
Brimblecombe
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||
Mr
G
Rezos
|
152,500
|
-
|
13
Oct 05
|
$
|
0.29
|
$
|
0.29
|
$
|
0.00
|
13
Oct 05
|
3
Feb 08
|
||||||||||||||
Dr
D
Mazzo
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||
Mr
M
Rogers
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||
Dr
P
Aston
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||
Total
|
152,500
|
-
|
|||||||||||||||||||||||
|
|||||||||||||||||||||||||
Other
key management personnel
|
|||||||||||||||||||||||||
Dr
M
Parry-Billings
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||
Mr
A
Finlay
|
-
|
*
10,000
|
13
Oct 05
|
$
|
0.29
|
$
|
0.29
|
$
|
0.00
|
-
|
3
Feb 08
|
||||||||||||||
Dr
A
Kluczewska
|
297,024
|
*
100,000
|
13
Oct 05
|
$
|
0.29
|
$
|
0.29
|
$
|
0.00
|
-
|
3
Feb 08
|
||||||||||||||
Prof
L Canham
|
-
|
*
45,000
|
13
Oct 05
|
$
|
0.29
|
$
|
0.29
|
$
|
0.00
|
-
|
3
Feb 08
|
||||||||||||||
Mr
S
Connor
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||
Dr
J
Ogden
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||
Ms
L
Freedman
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||
Mr
M
Soja
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||
Total
|
297,024
|
155,000
|
*
|
Vesting
of these options is subject to performance
conditions
|
**
|
Options
have been valued using the Black-Scholes option valuation model,
which
takes into account time value and the volatility of the stock
price.
|
Share
options issued by pSivida
Limited
|
2005
|
Terms
and conditions for each grant
|
||||||||||||||||||||||||
|
Vested
|
Granted
|
Grant
date
|
Value
per option at grant date **
|
Value
of underlying share at grant date
|
Exercise
price per share
|
Vesting
date
|
Expiry
date
|
|||||||||||||||||
|
Number
|
Number
|
$
|
$
|
$
|
|
|||||||||||||||||||
Directors
|
|||||||||||||||||||||||||
Dr
R
Brimblecombe
|
500,000
|
500,000
|
5
Aug 04
|
$
|
0.459
|
$
|
1.09
|
$
|
1.18
|
5
Aug 04
|
5
Aug 09
|
||||||||||||||
Mr
G
Rezos
|
2,750,000
|
2,750,000
|
5
Aug 04
|
$
|
0.459
|
$
|
1.09
|
$
|
1.18
|
5
Aug 04
|
5
Aug 09
|
||||||||||||||
Dr
R
Aston
|
1,000,000
|
1,000,000
|
5
Aug 04
|
|
$
|
0.459
|
$
|
1.09
|
$
|
1.18
|
5
Aug 04
|
5
Aug 09
|
|||||||||||||
Mr
S
Lake
|
200,000
|
200,000
|
5
Aug 04
|
$
|
0.459
|
$
|
1.09
|
$
|
1.18
|
5
Aug 04
|
5
Aug 09
|
||||||||||||||
Ms
A
Ledger
|
200,000
|
200,000
|
5
Aug 04
|
$
|
0.459
|
$
|
1.09
|
$
|
1.18
|
5
Aug 04
|
5
Aug 09
|
||||||||||||||
Total
|
4,650,000
|
4,650,000
|
|||||||||||||||||||||||
|
|||||||||||||||||||||||||
Other
key management personnel
|
|||||||||||||||||||||||||
Prof
L Canham
|
700,000
-
|
700,000
*
125,000
|
5
Aug 04
22
Apr 05
|
$
$
|
0.459
0.261
|
$
$
|
1.09
0.75
|
$
$
|
1.18
0.80
|
5
Aug 04
22
Apr 06
|
5
Aug 09
31
Mar 10
|
||||||||||||||
Mr
A
Finlay
|
700,000
-
|
700,000
200,000
|
5
Aug 04
22
Apr 05
|
$
$
|
0.459
0.261
|
$
$
|
1.09
0.75
|
$
$
|
1.18
0.80
|
5
Aug 04
22
Apr 06
|
5
Aug 09
31
Mar 10
|
||||||||||||||
Dr
A
Kluczewska
|
100,000
-
400,000
|
100,000
125,000
|
5
Aug 04
22
Apr 05
|
$
$
|
0.459
0.261
|
$
$
|
1.09
0.75
|
$
$
|
1.18
0.80
|
5
Aug 04
22
Apr 06
|
5
Aug 09
31
Mar 10
|
|
|||||||||||||
Mr
S
Connor
|
300,000
-
|
300,000
*
125,000
|
5
Aug 04
22
Apr 05
|
$
$
|
0.459
0.261
|
$
$
|
1.09
0.75
|
$
$
|
1.18
0.80
|
5
Aug 04
22
Apr 06
|
5
Aug 09
31
Mar 10
|
||||||||||||||
Dr
J
Ogden
|
300,000
-
|
300,000
*
125,000
|
5
Aug 04
22
Apr 05
|
$
$
|
0.459
0.261
|
$
$
|
1.09
0.75
|
$
$
|
1.18
0.80
|
5
Aug 04
22
Apr 06
|
5
Aug 09
31
Mar 10
|
||||||||||||||
Total
|
2,500,000
|
2,800,000
|
Share
options issued by AION Diagnostics
Limited
|
2005
|
Terms
and conditions for each grant
|
||||||||||||||||||||||||
|
Vested
|
Granted
|
Grant
date
|
Value
per option at grant date **
|
Value
of under-lying share at grant date
|
Exer-cise
price per share
|
Vesting
date
|
Expiry
date
|
|||||||||||||||||
|
Number
|
Number
|
$
|
$
|
$
|
|
|||||||||||||||||||
Directors
|
|||||||||||||||||||||||||
Mr
G
Rezos
|
-
|
*
250,000
|
3
Feb 05
|
$
|
0.40
|
$
|
0.40
|
Nil
|
3
Feb 08
|
||||||||||||||||
Dr
R
Aston
|
-
|
*
250,000
|
3
Feb 05
|
$
|
0.40
|
$
|
0.40
|
Nil
|
3
Feb 08
|
||||||||||||||||
Total
|
-
|
500,000
|
|||||||||||||||||||||||
|
|||||||||||||||||||||||||
Other
key management personnel
|
|||||||||||||||||||||||||
Prof
L Canham
|
-
|
*
65,840
|
3
Feb 05
|
$
|
0.40
|
$
|
0.40
|
Nil
|
3
Feb 08
|
||||||||||||||||
Mr
A
Finlay
|
-
|
*
98,760
|
3
Feb 05
|
$
|
0.40
|
$
|
0.40
|
Nil
|
3
Feb 08
|
||||||||||||||||
Dr
A
Kluczewska
|
-
|
*
395,040
|
3
Feb 05
|
$
|
0.40
|
$
|
0.40
|
Nil
|
3
Feb 08
|
||||||||||||||||
Total
|
-
|
559,640
|
*
|
Vesting
of these options is subject to performance
conditions
|
**
|
Options
have been valued using the Black Scholes Option Valuation Model,
which
takes into account time value and the volatility of the stock
price.
|
(f)
|
Shares
issued on exercise of compensation
options
|
No
compensation options were exercised by directors during the current
or
prior year.
|
(g)
|
Share
and option holdings of key management
personnel
|
Fully
paid ordinary shares of pSivida
Limited
|
2006
|
Balance
at
Jun
30, 2005
|
Granted
as compensation
|
Received
on exercise of options
|
Net
other change
|
Balance
at
Jun
30, 2006
|
|||||||||||
|
Number
|
Number
|
Number
|
Number
|
Number
|
|||||||||||
Directors
|
||||||||||||||||
Dr
R
Brimblecombe
|
445,067
|
-
|
-
|
168,133
|
613,200
|
|||||||||||
Mr
G
Rezos
|
11,319,282
|
-
|
-
|
171,000
|
11,490,282
|
|||||||||||
Mr
S
Lake
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Dr
D
Mazzo *
|
-
|
-
|
-
|
20,000
|
20,000
|
|||||||||||
Mr
M
Rogers *
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Dr
P
Ashton *
|
17,664,080
|
-
|
-
|
-
|
17,664,080
|
|||||||||||
Ms
H
Zampatti *
|
-
|
170,179
|
170,179
|
|||||||||||||
Ms
A
Ledger **
|
1,900,000
|
-
|
-
|
-
|
1,900,000
|
|||||||||||
Dr
R
Aston **
|
7,093,586
|
-
|
-
|
-
|
7,093,586
|
|||||||||||
Total
|
38,422,015
|
-
|
-
|
529,312
|
38,951,327
|
|||||||||||
|
||||||||||||||||
Other
key management personnel
|
||||||||||||||||
Dr
M
Parry-Billings
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Prof
L Canham
|
3,909,579
|
-
|
-
|
(179,579
|
)
|
3,730,000
|
||||||||||
Dr
A
Kluczewska
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Mr
M
Soja *
|
3,060,460
|
-
|
-
|
-
|
3,060,460
|
|||||||||||
Ms
L
Freedman *
|
2,786,320
|
-
|
-
|
-
|
2,786,320
|
|||||||||||
Mr
A
Finlay
|
-
|
-
|
-
|
15,000
|
15,000
|
|||||||||||
Dr
J
Ogden
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Mr
S
Connor
|
189,000
|
-
|
-
|
-
|
189,000
|
|||||||||||
Total
|
9,945,359
|
-
|
-
|
(164,579
|
)
|
9,780,780
|
* |
Opening
balance at date of appointment
|
** |
Closing
balance at date of resignation
|
2005
|
Balance
at
Jun
30, 2004
|
Granted
as compensation
|
Received
on exercise of options
|
Net
other change
|
Balance
at
Jun
30, 2005
|
|||||||||||
Number
|
Number
|
Number
|
Number
|
Number
|
||||||||||||
Directors
|
||||||||||||||||
Dr
R
Brimblecombe
|
320,833
|
-
|
-
|
124,234
|
445,067
|
|||||||||||
Mr
G
Rezos
|
10,895,657
|
-
|
-
|
423,625
|
11,319,282
|
|||||||||||
Dr
R
Aston
|
3,090,833
|
-
|
-
|
4,002,753
|
7,093,586
|
|||||||||||
Mr
S
Lake *
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Ms
A
Ledger *
|
2,000,000
|
-
|
-
|
(100,000
|
)
|
1,900,000
|
||||||||||
Mrs
N Donovan **
|
54,333
|
-
|
-
|
-
|
54,333
|
|||||||||||
Total
|
16,361,656
|
-
|
-
|
4,450,612
|
20,812,268
|
|||||||||||
|
||||||||||||||||
Other
key management personnel
|
||||||||||||||||
Prof
L Canham
|
-
|
-
|
-
|
3,909,579
|
3,909,579
|
|||||||||||
Mr
A
Finlay
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Dr
A
Kluczewska
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Mr
S
Connor
|
-
|
-
|
-
|
189,000
|
189,000
|
|||||||||||
Dr
J
Ogden
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Total
|
-
|
-
|
-
|
4,098,579
|
4,098,579
|
* |
Opening
balance at date of appointment
|
** |
Closing
balance at date of resignation
|
Share
options issued by pSivida
Limited
|
2006
|
Balance
at
Jun
30, 2005
|
Granted
as compensation
|
Exercised
|
Net
other change
|
Balance
at
Jun
30, 2006
|
Balance
vested and exercisable at Jun 30, 2006
|
Options
vested during year
|
|||||||||||||||
|
Number
|
Number
|
Number
|
Number
|
Number
|
Number
|
Number
|
|||||||||||||||
Directors
|
||||||||||||||||||||||
Dr
R
Brimblecombe
|
949,111
|
375,000
|
-
|
-
|
1,324,111
|
1,324,111
|
375,000
|
|||||||||||||||
Mr
G
Rezos
|
3,971,030
|
1,200,000
|
-
|
-
|
5,171,030
|
5,171,030
|
1,200,000
|
|||||||||||||||
Mr
S
Lake
|
242,061
|
-
|
-
|
-
|
242,061
|
242,061
|
-
|
|||||||||||||||
Dr
D
Mazzo *
|
-
|
200,000
|
-
|
-
|
200,000
|
-
|
-
|
|||||||||||||||
Mr
M
Rogers *
|
-
|
200,000
|
-
|
-
|
200,000
|
-
|
-
|
|||||||||||||||
Dr
P
Ashton *
|
-
|
500,000
|
-
|
880,700
|
1,380,700
|
880,700
|
-
|
|||||||||||||||
Ms
H
Zampatti *
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Ms
A
Ledger **
|
200,000
|
-
|
-
|
-
|
200,000
|
200,000
|
-
|
|||||||||||||||
Dr
R
Aston **
|
1,549,111
|
-
|
-
|
-
|
1,549,111
|
1,549,111
|
-
|
|||||||||||||||
Total
|
6,911,313
|
2,475,000
|
-
|
880,700
|
10,267,013
|
9,367,013
|
1,575,000
|
|||||||||||||||
|
||||||||||||||||||||||
Other
key management personnel
|
||||||||||||||||||||||
Dr
M
Parry-Billings
|
1,200,000
|
-
|
-
|
(80,000
|
)
|
1,120,000
|
720,000
|
320,000
|
||||||||||||||
Mr
A
Finlay
|
900,000
|
200,000
|
-
|
-
|
1,100,000
|
1,100,000
|
400,000
|
|||||||||||||||
Dr
A
Kluczewska
|
1,425,000
|
-
|
-
|
-
|
1,425,000
|
1,425,000
|
525,000
|
|||||||||||||||
Prof
L Canham
|
864,289
|
-
|
-
|
(12,500
|
)
|
851,789
|
851,789
|
112,500
|
||||||||||||||
Mr
S
Connor
|
444,645
|
-
|
-
|
-
|
444,645
|
444,645
|
125,000
|
|||||||||||||||
Dr
J
Ogden
|
554,708
|
-
|
-
|
(25,000
|
)
|
529,708
|
529,708
|
100,000
|
||||||||||||||
Ms
L
Freedman
|
-
|
237,500
|
-
|
-
|
237,500
|
-
|
-
|
|||||||||||||||
Mr
M
Soja
|
-
|
237,500
|
-
|
-
|
237,500
|
-
|
-
|
|||||||||||||||
Total
|
5,388,642
|
675,000
|
-
|
(117,500
|
)
|
5,946,142
|
5,071,142
|
1,582,500
|
* |
Opening
balance at date of appointment
|
** |
Closing
balance at date of resignation
|
2005
|
Balance
at
Jun
30, 2004
|
Granted
as compensation
|
Exercised
|
Net
other change
|
Balance
at
Jun
30, 2005
|
Balance
vested and exercisable at Jun 30, 2005
|
Options
vested during year
|
|||||||||||||||
|
Number
|
Number
|
Number
|
Number
|
Number
|
Number
|
Number
|
|||||||||||||||
Directors
|
||||||||||||||||||||||
Dr
R
Brimblecombe
|
1,000,000
|
500,000
|
-
|
(550,889
|
)
|
949,111
|
949,111
|
500,000
|
||||||||||||||
Mr
G
Rezos
|
5,450,000
|
2,750,000
|
-
|
(4,228,970
|
)
|
3,971,030
|
3,971,030
|
2,750,000
|
||||||||||||||
Dr
R
Aston
|
4,500,000
|
1,000,000
|
-
|
(3,950,889
|
)
|
1,549,111
|
1,549,111
|
1,000,000
|
||||||||||||||
Mr
S
Lake *
|
-
|
200,000
|
-
|
42,061
|
242,061
|
242,061
|
200,000
|
|||||||||||||||
Ms
A
Ledger *
|
-
|
200,000
|
-
|
-
|
200,000
|
200,000
|
200,000
|
|||||||||||||||
Mrs
N Donovan **
|
850,000
|
-
|
-
|
850,000
|
850,000
|
-
|
||||||||||||||||
Total
|
11,800,000
|
4,650,000
|
-
|
(8,688,687
|
)
|
7,761,313
|
7,761,313
|
4,650,000
|
||||||||||||||
|
||||||||||||||||||||||
Other
key management personnel
|
||||||||||||||||||||||
Prof
L Canham
|
-
|
825,000
|
-
|
39,289
|
864,289
|
739,289
|
700,000
|
|||||||||||||||
Mr
A
Finlay
|
-
|
900,000
|
-
|
-
|
900,000
|
700,000
|
700,000
|
|||||||||||||||
Dr
A
Kluczewska
|
1,200,000
|
225,000
|
-
|
-
|
1,425,000
|
900,000
|
500,000
|
|||||||||||||||
Mr
S
Connor
|
-
|
425,000
|
-
|
19,645
|
444,645
|
319,645
|
300,000
|
|||||||||||||||
Dr
J
Ogden
|
-
|
425,000
|
-
|
129,708
|
554,708
|
429,708
|
300,000
|
|||||||||||||||
|
1,200,000
|
2,800,000
|
-
|
188,642
|
4,188,642
|
3,088,642
|
2,500,000
|
* |
Opening
balance at date of appointment
|
** |
Closing
balance at date of resignation
|
Share
options issued by AION Diagnostics Consolidated
Group
|
2006
|
Balance
at
Jun
30, 2005
|
Granted
as compensation
|
Exercised
|
Net
other change
|
Balance
at
Jun
30, 2006
|
Balance
vested and exercisable at Jun 30, 2006
|
Options
vested during year
|
|||||||||||||||
|
Number
|
Number
|
Number
|
Number
|
Number
|
Number
|
Number
|
|||||||||||||||
Directors
|
||||||||||||||||||||||
Dr
R
Brimblecombe
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Mr
G
Rezos
|
250,000
|
-
|
-
|
-
|
250,000
|
152,500
|
152,500
|
|||||||||||||||
Mr
S
Lake
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Dr
D
Mazzo *
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Mr
M
Rogers *
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Dr
P
Ashton *
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Ms
H
Zampatti *
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Ms
A
Ledger **
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Dr
R
Aston **
|
250,000
|
-
|
-
|
(250,000
|
)
|
-
|
-
|
-
|
||||||||||||||
Total
|
500,000
|
-
|
-
|
(250,000
|
)
|
250,000
|
152,500
|
152,500
|
||||||||||||||
|
||||||||||||||||||||||
Other
key management personnel
|
||||||||||||||||||||||
Dr
M
Parry-Billings
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Mr
A
Finlay
|
98,760
|
10,000
|
-
|
-
|
108,760
|
-
|
-
|
|||||||||||||||
Dr
A
Kluczewska
|
395,040
|
100,000
|
-
|
-
|
495,040
|
297,024
|
297,024
|
|||||||||||||||
Prof
L Canham
|
65,840
|
45,000
|
-
|
-
|
110,840
|
-
|
-
|
|||||||||||||||
Mr
S
Connor
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Dr
J
Ogden
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Ms
L
Freedman
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Mr
M
Soja
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Total
|
559,640
|
155,000
|
-
|
-
|
714,640
|
297,024
|
297,024
|
* |
Opening
balance at date of appointment
|
** |
Closing
balance at date of resignation
|
2005
|
Balance
at
Jun
30, 2004
|
Granted
as compensation
|
Exercised
|
Net
other change
|
Balance
at
Jun
30, 2005
|
Balance
vested and exercisable at Jun 30, 2005
|
Options
vested during year
|
|||||||||||||||
|
Number
|
Number
|
Number
|
Number
|
Number
|
Number
|
Number
|
|||||||||||||||
Directors
|
||||||||||||||||||||||
Dr
R
Brimblecombe
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Mr
G
Rezos
|
-
|
250,000
|
-
|
-
|
250,000
|
-
|
-
|
|||||||||||||||
Mr
S
Lake *
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Ms
A
Ledger *
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Dr
R
Aston
|
-
|
250,000
|
-
|
-
|
250,000
|
-
|
-
|
|||||||||||||||
Mrs
N Donovan **
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Total
|
-
|
500,000
|
-
|
-
|
500,000
|
-
|
-
|
|||||||||||||||
|
||||||||||||||||||||||
Other
key management personnel
|
||||||||||||||||||||||
Dr
M
Parry-Billings
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Mr
A
Finlay
|
-
|
98,760
|
-
|
-
|
98,760
|
-
|
-
|
|||||||||||||||
Dr
A
Kluczewska
|
-
|
395,040
|
-
|
-
|
395,040
|
-
|
-
|
|||||||||||||||
Prof
L Canham
|
-
|
65,840
|
-
|
-
|
65,840
|
-
|
-
|
|||||||||||||||
Mr
S
Connor
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Dr
J
Ogden
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Ms
L
Freedman
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Mr
M
Soja
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Total
|
-
|
559,640
|
-
|
-
|
559,640
|
-
|
-
|
* |
Opening
balance at date of appointment
|
** |
Closing
balance at date of resignation
|
(h)
|
Other
transactions and balances with key management personnel and related
parties
|
24.
|
Auditor’s
remuneration
|
Years
Ended June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
Amounts
paid or due and payable to Deloitte Touche Tohmatsu Australia
for:
|
|||||||
- Audit
or review of the financial report of the entity and any other entity
in
the consolidated Group
|
262,916
|
-
|
|||||
-
Other
services in relation to the entity and any other entity in the
consolidated Group
|
|||||||
-
Taxation
services
|
12,217
|
-
|
|||||
-
Fees
incurred in relation to US statutory filings
|
404,494
|
643,704
|
|||||
|
679,627
|
643,704
|
|||||
Amounts
paid or due and payable to related practices of Deloitte Touche Tohmatsu
Australia for:
|
|||||||
-
Audit
or review of the financial report of subsidiaries
|
144,235
|
42,423
|
|||||
-
Taxation
services
|
41,119
|
9,496
|
|||||
- Fees
incurred in relation to US statutory filings
|
674,891
|
-
|
|||||
|
860,245
|
51,919
|
|||||
|
1,539,872
|
695,623
|
|||||
|
|||||||
Amounts
paid or due and payable to other audit firms for:
|
|||||||
- Audit
or review of the financial report of subsidiaries
|
27,569
|
34,737
|
|||||
- Taxation
services
|
4,307
|
-
|
|||||
- Corporate
finance services
|
83,645
|
72,920
|
|||||
|
115,521
|
107,657
|
25.
|
Acquisitions
of businesses
|
Names
of businesses acquired
|
Principal
activity
|
Date
of acquisition
|
Proportion
of shares acquired (%)
|
Cost
of acquisition
$
|
||||
2006
|
|
|
|
|
||||
Control
Delivery Systems Inc (‘CDS’)
|
Design
and develop drug delivery products
|
December
30, 2005
|
100%
|
116,878,675
|
Cost
of acquisition comprised of:
|
$
|
|||
·
Cash
|
114,319
|
|||
·
150,844,680
ordinary fully paid shares of pSivida, represented by 15,084,468
American
Depositary Shares (‘ADS’s)
$0.71 per share, represented by US$5.169 per ADS
|
107,099,723
|
|||
·
8,991,930
non-vested ordinary shares of pSivida, represented by 899,193 non-vested
ADSs
$0.71 per share, represented by US$5.169 per ADS
|
6,384,270
|
|||
·
Less:
Unearned compensation
|
(1,509,089
|
)
|
||
·
1,724,460
share options in pSivida, represented by 172,446 options over ADSs
|
642,250
|
|||
·
Direct
acquisition costs
|
4,147,202
|
|||
116,878,675
|
Control
Delivery Systems Inc (‘CDS’)
|
||||||||||
Net
assets acquired
|
Book
value
|
Fair
value adjustment
|
Fair
value on acquisition
|
|||||||
|
$
|
$
|
$
|
|||||||
Current
assets:
|
||||||||||
Cash
|
228,463
|
-
|
228,463
|
|||||||
Trade
and other receivables
|
545,633
|
-
|
545,633
|
|||||||
Prepayments
|
283,193
|
-
|
283,193
|
|||||||
Non-current
assets:
|
||||||||||
Property,
plant and equipment
|
624,082
|
-
|
624,082
|
|||||||
Deferred
tax assets
|
-
|
16,590,795
|
16,590,795
|
|||||||
In-process
R & D
|
-
|
34,281,686
|
34,281,686
|
|||||||
Patents
|
-
|
88,460,020
|
88,460,020
|
|||||||
Current
liabilities:
|
||||||||||
Trade
and other payables
|
(3,456,704
|
)
|
-
|
(3,456,704
|
)
|
|||||
Deferred
revenue
|
(1,826,700
|
)
|
-
|
(1,826,700
|
)
|
|||||
Provisions
|
(161,234
|
)
|
-
|
(161,234
|
)
|
|||||
Non-current
liabilities:
|
||||||||||
Deferred
tax liability
|
-
|
(49,096,682
|
)
|
(49,096,682
|
)
|
|||||
|
(3,763,267
|
)
|
90,235,819
|
86,472,552
|
||||||
Goodwill
on acquisition
|
30,406,123
|
|||||||||
116,878,675
|
26.
|
Segment
information
|
(a)
|
Business
segment - primary segment
|
(b)
|
Geographic
segment - secondary
segment
|
Segment
revenues
(i)
|
Long-lived
assets
|
||||||||||||
2006
|
2005
|
2006
|
2005
|
||||||||||
|
$
|
$
|
$
|
$
|
|||||||||
Australia
|
-
|
-
|
331,015
|
82,293
|
|||||||||
United
States
|
1,324,069
|
-
|
649,185
|
-
|
|||||||||
United
Kingdom
|
68,931
|
161,666
|
2,132,648
|
3,171,901
|
|||||||||
Singapore
|
-
|
-
|
26,701
|
19,469
|
|||||||||
Unallocated
|
-
|
-
|
-
|
-
|
|||||||||
Consolidated
|
1,393,000
|
161,666
|
3,139,549
|
3,273,663
|
(i)
|
Revenues
are attributed to countries based on location of
customer.
|
Segment
assets
|
Acquisition
of segment assets
|
||||||||||||
2006
|
2005
|
2006
|
2005
|
||||||||||
$
|
$
|
$
|
$
|
||||||||||
Australia
|
12,669,836
|
11,059,134
|
292,661
|
7,475
|
|||||||||
United
States
|
151,191,558
|
-
|
153,630,779
|
-
|
|||||||||
United
Kingdom
|
69,300,275
|
78,174,497
|
953,223
|
83,578,841
|
|||||||||
Singapore
|
2,201,143
|
2,278,670
|
19,147
|
20,836
|
|||||||||
Unallocated
|
123,265
|
353,801
|
26,208
|
49,444
|
|||||||||
Consolidated
|
235,486,077
|
91,866,102
|
154,922,018
|
83,656,596
|
27.
|
Financial
instruments
|
(a)
|
Financial
risk management objectives
|
(b)
|
Significant
accounting policies
|
(c)
|
Foreign
currency risk management
|
(d)
|
Interest
rate risk management
|
|
|
|
|
|
Fixed
interest rate
|
||||||||||||||||||||
Notes
|
interest
rate
|
Less
than 1 year
|
1-5
years
|
More
than 5 years
|
Non-interest
bearing
|
Total
|
Weighted
average interest rate
|
||||||||||||||||||
$
|
$
|
$
|
$
|
$
|
$
|
$
|
%
|
||||||||||||||||||
2006
|
|||||||||||||||||||||||||
Financial
assets
|
|||||||||||||||||||||||||
Cash
|
17(a)
|
|
15,028,210
|
-
|
-
|
-
|
418,342
|
15,446,552
|
4.04
|
%
|
|||||||||||||||
Trade
and other receivables
|
5
|
-
|
-
|
-
|
-
|
1,001,486
|
1,001,486
|
-
|
|||||||||||||||||
|
15,028,210
|
-
|
-
|
-
|
1,419,828
|
16,448,038
|
|||||||||||||||||||
|
|||||||||||||||||||||||||
Financial
liabilities
|
|||||||||||||||||||||||||
Trade
creditors and accruals
|
9
|
-
|
-
|
-
|
-
|
7,416,013
|
7,416,013
|
-
|
|||||||||||||||||
Deferred
revenue
|
-
|
-
|
-
|
-
|
2,668,574
|
2,668,574
|
|||||||||||||||||||
Borrowings
|
10
|
-
|
11,219,696
|
3,940,092
|
-
|
-
|
15,159,788
|
8.0
|
%
|
||||||||||||||||
Other
financial liabilities
|
11
|
-
|
-
|
-
|
-
|
2,465,416
|
2,465,416
|
-
|
|||||||||||||||||
|
-
|
11,219,696
|
3,940,092
|
-
|
12,550,003
|
27,709,791
|
|||||||||||||||||||
|
|||||||||||||||||||||||||
2005
|
|||||||||||||||||||||||||
Financial
assets
|
|||||||||||||||||||||||||
Cash
|
17(a)
|
|
12,528,926
|
200,000
|
-
|
-
|
163,135
|
12,892,061
|
2.87
|
%
|
|||||||||||||||
Trade
and other receivables
|
5
|
-
|
-
|
-
|
-
|
709,418
|
709,418
|
-
|
|||||||||||||||||
|
12,528,926
|
200,000
|
-
|
-
|
872,553
|
13,601,479
|
|||||||||||||||||||
|
|||||||||||||||||||||||||
Financial
liabilities
|
|||||||||||||||||||||||||
Trade
creditors and accruals
|
9
|
-
|
-
|
-
|
-
|
2,017,820
|
2,017,820
|
-
|
|||||||||||||||||
|
-
|
-
|
-
|
-
|
2,017,820
|
2,017,820
|
(e)
|
Credit
risk management
|
(f)
|
Fair
value of financial
instruments
|
28.
|
Transition
to Australian equivalents to International Financial Reporting
Standards
|
Consolidated
|
|||||||||||||
Notes
|
Superseded
policies *
|
Effect
of transition to
A-IFRS
|
A-IFRS
|
||||||||||
$
|
$
|
$
|
|||||||||||
Current
assets
|
|||||||||||||
Cash
and cash equivalents
|
31,350,656
|
-
|
31,350,656
|
||||||||||
Trade
and other receivables
|
340,482
|
-
|
340,482
|
||||||||||
Prepayments
|
38,958
|
-
|
38,958
|
||||||||||
Total
current assets
|
31,730,096
|
-
|
31,730,096
|
||||||||||
|
|||||||||||||
Non-current
assets
|
|||||||||||||
Property,
plant and equipment
|
669,699
|
-
|
669,699
|
||||||||||
Other
intangible assets
|
a
|
7,934,622
|
1,183,550
|
9,118,172
|
|||||||||
Other
|
32,641
|
-
|
32,641
|
||||||||||
Total
non-current assets
|
8,636,962
|
1,183,550
|
9,820,512
|
||||||||||
|
|||||||||||||
Total
assets
|
40,367,058
|
1,183,550
|
41,550,608
|
||||||||||
|
|||||||||||||
Current
liabilities
|
|||||||||||||
Trade
and other payables
|
1,938,115
|
-
|
1,938,115
|
||||||||||
Total
current liabilities
|
1,938,115
|
-
|
1,938,115
|
||||||||||
|
|||||||||||||
Total
liabilities
|
1,938,115
|
-
|
1,938,115
|
||||||||||
|
|||||||||||||
Net
assets
|
38,428,943
|
1,183,550
|
39,612,493
|
||||||||||
|
|||||||||||||
Equity
|
|||||||||||||
Issued
capital
|
49,957,982
|
-
|
49,957,982
|
||||||||||
Reserves
|
b,
c
|
78,220
|
(38,531
|
)
|
39,689
|
||||||||
Accumulated
losses
|
g
|
(13,190,459
|
)
|
1,222,081
|
(11,968,378
|
)
|
|||||||
Parent
entity interest
|
36,845,743
|
1,183,550
|
38,029,293
|
||||||||||
Minority
interest
|
1,583,200
|
-
|
1,583,200
|
||||||||||
|
|||||||||||||
Total
equity
|
38,428,943
|
1,183,550
|
39,612,493
|
* |
Reported
financial position as at June 30,
2004.
|
Consolidated
|
|||||||||||||
Notes
|
Superseded
policies *
|
Effect
of transition to
A-IFRS
|
A-IFRS
|
||||||||||
$
|
$
|
$
|
|||||||||||
Revenue
|
d
|
828,976
|
(667,310
|
)
|
161,666
|
||||||||
Other
income
|
d
|
-
|
660,400
|
660,400
|
|||||||||
Selling,
general and administrative
|
a,
c, e
|
(6,011,712
|
)
|
(5,681,294
|
)
|
(11,693,006
|
)
|
||||||
Research
and development
|
(8,287,930
|
)
|
-
|
(8,287,930
|
)
|
||||||||
Finance
costs
|
(31,569
|
)
|
-
|
(31,569
|
)
|
||||||||
Foreign
exchange gain / (loss), net
|
(1,623,484
|
)
|
-
|
(1,623,484
|
)
|
||||||||
Loss
before income tax
|
(15,125,719
|
)
|
(5,688,204
|
)
|
(20,813,923
|
)
|
|||||||
Income
tax benefit
|
f
|
-
|
3,620,891
|
3,620,891
|
|||||||||
Loss
for the period
|
(15,125,719
|
)
|
(2,067,313
|
)
|
(17,193,032
|
)
|
|||||||
Loss
attributable to minority interest
|
399,196
|
-
|
399,196
|
||||||||||
Loss
attributable to members of the parent entity
|
(14,726,523
|
)
|
(2,067,313
|
)
|
(16,793,836
|
)
|
*
|
Reported
financial results under previous Australian
GAAP.
|
Consolidated
|
|||||||||||||
Notes
|
Superseded
policies *
|
Effect
of transition to
A-IFRS
|
A-IFRS
|
||||||||||
$
|
$
|
$
|
|||||||||||
Current
assets
|
|||||||||||||
Cash
and cash equivalents
|
12,892,061
|
-
|
12,892,061
|
||||||||||
Trade
and other receivables
|
709,418
|
-
|
709,418
|
||||||||||
Prepayments
|
322,933
|
-
|
322,933
|
||||||||||
Total
current assets
|
13,924,412
|
-
|
13,924,412
|
||||||||||
|
|||||||||||||
Non-current
assets
|
|||||||||||||
Property,
plant and equipment
|
3,273,663
|
-
|
3,273,663
|
||||||||||
Goodwill
|
e
|
8,588,228
|
14,717,470
|
23,305,698
|
|||||||||
Other
intangible assets
|
a
|
56,249,010
|
(4,886,681
|
)
|
51,362,329
|
||||||||
Total
non-current assets
|
68,110,901
|
9,830,789
|
77,941,690
|
||||||||||
|
|||||||||||||
Total
assets
|
82,035,313
|
9,830,789
|
91,866,102
|
||||||||||
|
|||||||||||||
Current
liabilities
|
|||||||||||||
Trade
and other payables
|
2,017,820
|
-
|
2,017,820
|
||||||||||
Provisions
|
29,879
|
-
|
29,879
|
||||||||||
Total
current liabilities
|
2,047,699
|
-
|
2,047,699
|
||||||||||
|
|||||||||||||
Non-current
liabilities
|
|||||||||||||
Deferred
tax liabilities
|
f
|
-
|
10,122,656
|
10,122,656
|
|||||||||
Total
non-current liabilities
|
-
|
10,122,656
|
10,122,656
|
||||||||||
|
|||||||||||||
Total
liabilities
|
2,047,699
|
10,122,656
|
12,170,355
|
||||||||||
|
|||||||||||||
Net
assets
|
79,987,614
|
(291,867
|
)
|
79,695,747
|
|||||||||
|
|||||||||||||
Equity
|
|||||||||||||
Issued
capital
|
107,883,835
|
-
|
107,883,835
|
||||||||||
Reserves
|
b,
c
|
20,761
|
553,366
|
574,127
|
|||||||||
Accumulated
losses
|
g
|
(27,916,982
|
)
|
(845,233
|
)
|
(28,762,215
|
)
|
||||||
|
|||||||||||||
Total
equity
|
79,987,614
|
(291,867
|
)
|
79,695,747
|
* |
Reported
financial position under previous Australian
GAAP.
|
(a)
|
Other
intangible assets
|
(b)
|
Cumulative
exchange differences
|
(c) |
Share-based
payments
|
(d) |
Interest
income
|
(e) |
Goodwill
|
(f) |
Deferred
income tax
|
Consolidated
|
|||||||
July
1, 2004
|
June
30, 2005
|
||||||
$
|
$
|
||||||
Deferred
tax assets not recognized under previous AGAAP
|
2,708,039
|
5,611,096
|
|||||
Deferred
tax liabilities not recognized under previous AGAAP
|
(2,708,039
|
)
|
(15,733,752
|
)
|
|||
Net
increase in deferred tax balances
|
-
|
(10,122,656
|
)
|
Financial
year ended
June
30, 2005
|
||||
$
|
||||
Net
impact on deferred tax at beginning of period
|
-
|
|||
Impact
on loss for period
|
3,620,892
|
|||
Deferred
tax capitalized to goodwill
|
(13,743,548
|
)
|
||
Net
impact of deferred tax at end of period
|
(10,122,656
|
)
|
(g) |
Accumulated
losses
|
Consolidated
|
||||||||||
Notes
|
July
1, 2004
|
June
30, 2005
|
||||||||
$
|
$
|
|||||||||
Income
tax benefit / expense
|
a,
f
|
3,400,552
|
7,021,443
|
|||||||
Direct
acquisition costs capitalized
|
b
|
112,278
|
112,278
|
|||||||
Amortization
of grossed-up intangible
|
b
|
(692,513
|
)
|
(1,003,517
|
)
|
|||||
Amortization
of intangibles previously unamortized
|
b
|
(1,636,767
|
)
|
(7,395,994
|
)
|
|||||
Transfer
from foreign currency translation reserve
|
c
|
78,220
|
78,220
|
|||||||
Expensed
share-based payments
|
d
|
(39,689
|
)
|
(631,586
|
)
|
|||||
Goodwill
no longer amortized
|
e
|
-
|
973,923
|
|||||||
|
||||||||||
Total
adjustment to accumulated losses
|
1,222,081
|
(845,233
|
)
|
|||||||
|
||||||||||
Attributable
to members of the parent entity
|
1,222,081
|
(845,233
|
)
|
|||||||
Attributable
to minority interest
|
-
|
-
|
||||||||
|
1,222,081
|
(845,233
|
)
|
29. |
Reconciliation
to US GAAP
|
Year
ended
|
||||||||||
June
30, 2006
|
June
30, 2005
|
|||||||||
$
|
$
|
|||||||||
Loss
for the period in accordance with A-IFRS
|
(28,166,129
|
)
|
(17,193,032
|
)
|
||||||
Loss
attributable to minority interest
|
-
|
399,196
|
||||||||
Loss
attributable to members of the parent entity under A-IFRS
|
(28,166,129
|
)
|
(16,793,836
|
)
|
||||||
|
||||||||||
US
GAAP adjustments:
|
||||||||||
Share-based
compensation expense
|
a
|
-
|
310,674
|
|||||||
Fair
value of equity instruments issued as consideration - amortization
expense
|
b
|
(35,911
|
)
|
(42,811
|
)
|
|||||
In-process
research and development
|
c
|
(35,059,623
|
)
|
-
|
||||||
Sales
of stock by subsidiaries - amortization expense
|
d
|
(39,529
|
)
|
(39,232
|
)
|
|||||
Sale
and leaseback transaction - deferred gain
|
e
|
100,685
|
-
|
|||||||
Deferred
tax effect of US GAAP adjustments
|
(280,619
|
)
|
24,613
|
|||||||
US
GAAP adjustments attributable to minority interest
|
-
|
(20,920
|
)
|
|||||||
|
||||||||||
Net
loss in accordance with US GAAP
|
(63,481,126
|
)
|
(16,561,512
|
)
|
||||||
|
||||||||||
Loss
per share in accordance with US GAAP
|
||||||||||
Basic
and diluted loss per share
|
f
|
$
|
(0.21
|
)
|
$
|
(0.08
|
)
|
|||
Weighted
average number of shares - basic and diluted
|
305,882,956
|
207,802,540
|
As
of
|
||||||||||
June
30, 2006
|
June
30, 2005
|
|||||||||
Total
equity in accordance with A-IFRS
|
175,032,585
|
79,695,747
|
||||||||
|
||||||||||
US
GAAP adjustments:
|
||||||||||
Fair
value of equity instruments issued as consideration
|
b
|
33,542,628
|
8,410,076
|
|||||||
In-process
research and development
|
c
|
(36,094,641
|
)
|
(1,035,018
|
)
|
|||||
Sales
of stock by subsidiaries
|
d
|
272,806
|
312,335
|
|||||||
Sale
and leaseback transaction
|
e
|
100,685
|
-
|
|||||||
Deferred
tax impact of US GAAP adjustments
|
(13,422
|
)
|
267,197
|
|||||||
Foreign
currency translation impact of US GAAP adjustments
|
(242,508
|
)
|
-
|
|||||||
|
||||||||||
Total
equity in accordance with US GAAP
|
172,598,133
|
87,650,337
|
Year
ended
|
||||||||||
June
30, 2006
|
June
30, 2005
|
|||||||||
Balance
in accordance with US GAAP at beginning of year
|
87,650,337
|
37,794,705
|
||||||||
Issuance
of equity instruments in connection with acquisitions, net of issue
and
registration costs
|
136,616,233
|
62,819,709
|
||||||||
Issuance
of shares in connection with PIPE and rights issue, net of issue
costs
|
10,988,862
|
-
|
||||||||
Issuance
of shares in connection with exercise of options
|
15
|
3,666,500
|
||||||||
Share-based
compensation attributable to non-vested ADSs, options and warrants
issued
|
a
|
2,033,396
|
281,222
|
|||||||
Warrants
attached to convertible loan note
|
1,706,592
|
-
|
||||||||
Foreign
currency translation adjustment
|
(2,916,176
|
)
|
(350,287
|
)
|
||||||
Net
loss in accordance with US GAAP
|
(63,481,126
|
)
|
(16,561,512
|
)
|
||||||
Balance
in accordance with US GAAP at end of year
|
172,598,133
|
87,650,337
|
(a) |
Share-based
compensation expense
|
Year
ended
June
30, 2005
|
||||
US
GAAP net loss, as reported
|
(16,561,512
|
)
|
||
Add:
Stock-based employee compensation expense included in reported US
GAAP net
loss
|
125,018
|
|||
Deduct:
Total stock-based employee compensation expense determined under
fair
value based method
|
(4,537,993
|
)
|
||
US
GAAP pro forma net loss
|
(20,974,487
|
)
|
||
US
GAAP basic and diluted loss per share
|
||||
As
reported
|
$
|
(0.08
|
)
|
|
Pro
forma
|
$
|
(0.10
|
)
|
(b) |
Fair
value of equity instruments issued as
consideration
|
(c) |
In-process
research and development
|
(d) |
Sales
of stock by subsidiaries
|
(e) |
Sale
and leaseback transaction
|
(f) |
Loss
per share
|
(g) |
Foreign
currency translation
adjustment
|
(h) |
Convertible
note
|
(i) |
Balance
sheet classification
differences
|
(j) |
Statement
of operation differences
|
(k) |
Other
|
30. |
Additional
disclosures
|
(a) |
Intangible
assets
|
(b)
|
Income
tax
|
Years
Ended June 30,
|
|||||||
2006
|
2005
|
||||||
$
|
$
|
||||||
United
States
|
(9,638,598
|
)
|
-
|
||||
Australia
|
(10,474,732
|
)
|
(8,182,730
|
)
|
|||
United
Kingdom
|
(16,428,446
|
)
|
(11,173,086
|
)
|
|||
Singapore
|
(1,144,158
|
)
|
(1,458,107
|
)
|
|||
Total
|
(37,685,934
|
)
|
(20,813,923
|
)
|
(c)
|
Share-based
payments
|
Year
ended June 30,
|
|||||||||||||
2006
|
2005
|
||||||||||||
Number
of options
|
Weighted
average exercise price
$
|
Number
of options
|
Weighted
average exercise price
$
|
||||||||||
Outstanding
at beginning of year
|
3,130,000
|
1.00
|
500,000
|
0.61
|
|||||||||
Granted
|
-
|
2,630,000
|
1.07
|
||||||||||
Forfeited
|
(10,000
|
)
|
1.18
|
||||||||||
Outstanding
at end of year
|
3,120,000
|
1.00
|
3,130,000
|
1.00
|
|||||||||
Exercisable
at end of year
|
2,920,000
|
0.95
|
2,930,000
|
0.95
|
Range
of exercise price
|
Number
of options
|
Weighted
average exercise price
|
|||||
$0.50
to $0.75
|
500,000
|
$
|
0.61
|
||||
$0.75
to $1.00
|
165,000
|
$
|
0.80
|
||||
$1.00
to $1.25
|
2,455,000
|
$
|
1.09
|
||||
3,120,000
|
Year
ended June 30,
|
|||||||
2006
|
|||||||
Number
of warrants over ADSs
|
Weighted
average exercise price
US$
|
||||||
Outstanding
at beginning of year
|
-
|
-
|
|||||
Granted
|
133,000
|
12.50
|
|||||
Outstanding
at end of year
|
133,000
|
12.50
|
|||||
Exercisable
at end of year
|
133,000
|
12.50
|
(d)
|
Development
stage
|
Period
from inception of development stage (Dec 1, 2000) to June 30,
2006
|
||||
$
|
||||
Revenue
|
1,612,995
|
|||
Other
income
|
1,992,328
|
|||
Research
and development
|
(41,154,037
|
)
|
||
Selling,
general and administrative
|
(40,241,999
|
)
|
||
Finance
costs
|
(4,581,289
|
)
|
||
Change
in fair value of derivative
|
3,407,915
|
|||
Foreign
exchange gain
|
561,699
|
|||
|
||||
Loss
before income tax benefit
|
(78,402,388
|
)
|
||
Income
tax benefit
|
16,541,249
|
|||
|
||||
Loss
for the period
|
(61,861,139
|
)
|
||
Loss
attributable to minority interest
|
8,745,976
|
|||
|
||||
Loss
attributable to members of the parent entity
|
(53,115,163
|
)
|
Period
from inception of development stage (December 1, 2000) to June 30,
2006
|
||||
$
|
||||
Cash
flows from operating activities
|
||||
Receipts
from customers
|
1,982,174
|
|||
Payments
to suppliers, employees and consultants
|
(20,323,790
|
)
|
||
Research
and development expenditure
|
(34,106,553
|
)
|
||
Interest
received
|
1,932,327
|
|||
Other
income
|
260,200
|
|||
Income
received in advance
|
486,780
|
|||
Interest
expense
|
(1,014,534
|
)
|
||
|
||||
Net
cash used in operating activities
|
(50,783,396
|
)
|
||
|
||||
Cash
flows from investing activities
|
||||
Purchase
of property, plant and equipment
|
(6,392,038
|
)
|
||
Proceeds
on sale of property, plant and equipment
|
728,460
|
|||
Net
cash paid for acquisitions of businesses
|
(4,033,058
|
)
|
||
Net
cash paid for increased interest in subsidiaries
|
(3,915,058
|
)
|
||
|
||||
Net
cash used in investing activities
|
(13,611,694
|
)
|
||
|
||||
Cash
flows from financing activities
|
||||
Proceeds
from issue of ordinary shares
|
58,488,391
|
|||
Payment
of share issue costs
|
(4,426,899
|
)
|
||
Proceeds
from borrowings
|
20,500,500
|
|||
Payment
of borrowing costs
|
(1,238,959
|
)
|
||
Equity
contributions from minority interest
|
5,508,030
|
|||
|
||||
Net
cash provided by financing activities
|
78,831,063
|
|||
|
||||
Net
increase in cash and cash equivalents
|
14,435,973
|
|||
Cash
and cash equivalents at the beginning of the period
|
597,000
|
|||
Effects
of exchange rate changes on the balance of cash held in foreign
currencies
|
413,579
|
|||
Cash
and cash equivalents at the end of the period
|
15,446,552
|
Number
of shares
|
Contributed
equity
|
||||||
$
|
|||||||
Balance
at inception of development stage - December 1, 2000
|
62,329,947
|
6,060,181
|
|||||
Issue
of shares in connection with placement at $0.30 per share, net of
issue
costs - December 1, 2000
|
9,300,000
|
2,773,709
|
|||||
Non-cash
issue of shares as consideration for acquisition at $0.30 per share,
net
of issue costs - May 10, 2001
|
10,918,535
|
3,273,959
|
|||||
Balance
June 30, 2001
|
82,548,482
|
12,107,849
|
|||||
Issue
of shares in connection with placement at $0.20 per share, net of
issue
costs - November 22, 2001
|
12,300,000
|
2,332,410
|
|||||
Issue
of shares in connection with share purchase plan at $0.22 per share,
net
of issue costs - May 9, 2002
|
998,500
|
209,357
|
|||||
Balance
June 30, 2002
|
95,846,982
|
14,649,616
|
|||||
Issue
of shares in connection with placement at $0.12 per share, net of
issue
costs - October 10, 2002
|
7,000,000
|
792,568
|
|||||
Non-cash
issue of shares in lieu of director’s fees at $0.13 per share - November
25, 2002
|
769,231
|
100,000
|
|||||
Issue
of shares pursuant to exercise of stock options at $0.20 per share
- June
19, 2003
|
300,000
|
60,000
|
|||||
Balance
June 30, 2003
|
103,916,213
|
15,602,184
|
|||||
Issue
of shares in connection with share purchase plan at $0.24 per share,
net
of issue costs - August 4, 2003
|
3,891,572
|
932,297
|
|||||
Issue
of shares pursuant to exercise of stock options at $0.20 per share
-
August 2003 to May 2004
|
8,130,000
|
1,626,000
|
|||||
Non-cash
issue of shares as consideration for acquisition at $0.50 per share,
net
of issue costs - October 6, 2003
|
13,000,000
|
6,161,600
|
|||||
Issue
of shares in connection with placement at $1.09 per share, net of
issue
costs - April 20, 2004
|
19,375,000
|
19,308,011
|
|||||
Issue
of shares in connection with placement at $1.16 per share, net of
issue
costs - April 23, 2004
|
5,625,000
|
6,327,890
|
|||||
Balance
June 30, 2004
|
153,937,785
|
49,957,982
|
|||||
Non-cash
issue of shares as consideration for acquisition at $1.09 per share,
net
of issue costs - August 5, 2004
|
49,804,381
|
54,259,353
|
|||||
Issue
of shares pursuant to exercise of stock options at $0.20 per share
- July
2004 to December 2004
|
13,070,000
|
2,614,000
|
|||||
Issue
of shares pursuant to exercise of stock options at $0.40 per share
-
October 2004 to December 2004
|
2,200,000
|
880,000
|
|||||
Issue
of shares pursuant to exercise of stock options at $0.50 per share
-
December 14, 2004
|
150,000
|
75,000
|
|||||
Issue
of shares pursuant to exercise of stock options at $0.65 per share
-
December 14, 2004
|
150,000
|
97,500
|
|||||
Balance
June 30, 2005
|
219,312,166
|
107,883,835
|
|
Number
of shares
|
Contributed
equity
|
|||||
$
|
|||||||
Issue
of shares in connection with PIPE at $0.848 per share, net of issue
costs
- September 5, 2005
|
6,650,000
|
4,842,372
|
|||||
Non-cash
issue of shares as consideration for acquisition at $0.71 per share,
net
of issue costs - December 30, 2005
|
159,836,610
|
110,805,519
|
|||||
Non-cash
issue of non-vested ADSs to CDS employees in relation to salaries
and
wages as part of the CDS acquisition - December 30, 2005
|
1,211,180
|
-
|
|||||
Issue
of shares pursuant to exercise of stock options at $0.71 per share
- April
21, 2006
|
38,740
|
27,521
|
|||||
Forfeiture
of nonvested ADSs issued as part of CDS acquisition - April
2006
|
(528,400
|
)
|
(291,174
|
)
|
|||
Issue
of shares pursuant to rights issue at $0.60 per share - June 15,
2006
|
10,515,811
|
6,146,490
|
|||||
Amortisation
of non-vested ADSs issued as part of the CDS acquisition
|
-
|
962,471
|
|||||
Balance
June 30, 2006
|
397,036,107
|
230,377,034
|
(e)
|
Recently
issued but not yet adopted US GAAP
pronouncements
|